[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 114
1. Karube K, Aoki R, Sugita Y, Yoshida S, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Takeshita M, Suzumiya J, Utsunomiya A, Kikuchi M, Ohshima K: The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma. Mod Pathol; 2008 May;21(5):617-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma is an aggressive malignant disease associated with regulatory T cells as discussed in some recent reports.
  • We analyzed the expression of FOXP3, a key molecule of regulatory T cells, in adult T-cell leukemia/lymphoma and its association with clinicopathological features.
  • Of 169 adult T-cell leukemia/lymphoma cases examined, 60 (36%) showed FOXP3 expression in lymphoma cells.
  • Morphologically, 22 cases were classified as anaplastic large cell variant and 147 as pleomorphic cell variant.
  • Only 1 (5%) of the anaplastic large cell variant cases and 59/147 (40%) of the pleomorphic cell variant cases expressed FOXP3.
  • Clinically, FOXP3(+) and FOXP3(-) cases did not differ significantly in age distribution, clinical stage, lactate dehydrogenase and calcium in serum and overall survival.
  • FOXP3 expression in adult T-cell leukemia/lymphoma thus reflects morphological features and is clinically and pathologically associated with an immunosuppressive state.
  • [MeSH-major] Forkhead Transcription Factors / biosynthesis. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Southern. Epstein-Barr Virus Infections / metabolism. Female. Herpesvirus 4, Human. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246047.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


2. Nishioka C, Takemoto S, Kataoka S, Yamanaka S, Moriki T, Shoda M, Watanabe T, Taguchi H: Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci; 2005 Nov;96(11):810-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive disease with poor prognosis.
  • Both mCD30 and sCD30 are expressed on various numbers of ATL cells in vivo as well as cell lines such as MT-2, L540 and Karpas 299.
  • The level of serum sCD30 in each clinical stage showed an elevated level in patients with acute type (mean +/- standard error; 545.2 +/- 18.6 U/mL) rather than with lymphoma type ATL (327.62 +/- 94.85 U/mL).
  • [MeSH-major] Antigens, CD30 / analysis. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Longitudinal Studies. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271075.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K: Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci; 2008 May;99(5):1016-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
  • Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are rare, and their standard therapy has not been established.
  • They are Epstein-Barr virus-associated lymphoid malignancies, and tumor cells express P-glycoprotein leading to multidrug resistance of the disease.
  • Patients with stage IV, relapsed or refractory diseases have a dismal prognosis, with survival measured in months only.
  • Etoposide shows both in vitro and in vivo efficacy for Epstein-Barr virus-associated lymphoproliferative disorders.
  • Eligible patients had newly diagnosed stage IV, relapsed or refractory diseases after first-line chemotherapy, were 15-69 years of age, and had satisfactory performance scores (0-2).
  • At level 1, six patients with extranodal NK/T-cell lymphoma, nasal type, were enrolled.
  • Their disease status was newly diagnosed stage IV (n = 3), first relapse (n = 2), and primary refractory (n = 1).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphoid / drug therapy. Lymphoma, Extranodal NK-T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Asparaginase / administration & dosage. Asparaginase / therapeutic use. Dexamethasone / administration & dosage. Dexamethasone / therapeutic use. Etoposide / administration & dosage. Etoposide / therapeutic use. Humans. Ifosfamide / administration & dosage. Ifosfamide / therapeutic use. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294294.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.1 / Asparaginase; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Wołowiec D, Dybko J, Wróbel T, Urbaniak-Kujda D, Jaźwiec B, Tomaszewska-Toporska B, Kapelko-Słowik K, Potoczek S, Kuliczkowski K: Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm; 2006;2006(3):42394
Genetic Alliance. consumer health - Leukemia, B-cell, chronic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia.
  • Its prognostic value in B-cell chronic lymphocytic leukemia (B-CLL) has not been evaluated so far.
  • Moreover, high sCD138 level was associated with longer lymphocyte doubling-free survival, and, on the limit of statistical significance, a high endostatin level was associated with shorter progression-free survival.
  • We conclude that serum sCD138 level is increased in early stage B-CLL patients and may have a positive prognostic value as to the dynamics of the disease.
  • [MeSH-major] Endostatins / blood. Fibroblast Growth Factor 2 / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Membrane Glycoproteins / blood. Proteoglycans / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Syndecan-1. Syndecans

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Aug;106(2):504-9 [10460612.001]
  • [Cites] Annu Rev Cell Biol. 1992;8:365-93 [1335744.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1414-8 [10942237.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2240-5 [10979972.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3181-7 [11050001.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4628-34 [11156212.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1525-9 [11301401.001]
  • [Cites] Br J Haematol. 2001 May;113(2):400-6 [11380405.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):14-7 [11815955.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):31-5 [11857008.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3344-51 [12384436.001]
  • [Cites] Mediators Inflamm. 2003 Jun;12(3):167-71 [12857600.001]
  • [Cites] Cell. 1991 Mar 8;64(5):867-9 [2001586.001]
  • [Cites] Cell Regul. 1989 Nov;1(1):27-35 [2519615.001]
  • [Cites] Adv Cancer Res. 1992;59:115-65 [1381547.001]
  • [Cites] Blood. 1993 Feb 1;81(3):767-74 [8427968.001]
  • [Cites] Leukemia. 1994 Mar;8(3):523-9 [7510358.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3010-6 [7949173.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):2975-82 [7698997.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1978-80 [7772131.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Leukemia. 1997 Feb;11(2):258-65 [9009090.001]
  • [Cites] Br J Haematol. 1997 Nov;99(2):368-71 [9375756.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2679-88 [9531576.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):167-75 [9720726.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):412-9 [10050727.001]
  • [Cites] Blood. 2000 Jan 15;95(2):388-92 [10627439.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):761-2 [10942069.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):605-10 [10583266.001]
  • (PMID = 16951490.001).
  • [ISSN] 0962-9351
  • [Journal-full-title] Mediators of inflammation
  • [ISO-abbreviation] Mediators Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endostatins; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  • [Other-IDs] NLM/ PMC1592593
  •  go-up   go-down


5. Miyahara H, Itou H, Sekine A, Taniyama D, Katsui T, Tanaka W, Satou R, Kurihara A, Satou Y, Sakamaki F: [A case of adult T-cell leukemia/lymphoma with primary lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):342-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult T-cell leukemia/lymphoma with primary lung cancer].
  • The mass was pathologically diagnosed as adult T-cell leukemia/lymphoma (ATLL) because of a high HTLV-1 antibody titer, and radiation therapy was started.
  • We diagnosed stage IV primary lung cancer and started chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455967.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Osaka A, Yanagihara K, Yamada Y, Hasegawa H, Inokuchi N, Hayashi T, Komoda M, Nakamura S, Aoyama M, Sawada T, Kamihira S: Elevation of serum KL-6 glycoprotein or surfactant protein-D in adult T-cell leukemia with distinct pulmonary complications. Tohoku J Exp Med; 2009 Jun;218(2):99-105
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of serum KL-6 glycoprotein or surfactant protein-D in adult T-cell leukemia with distinct pulmonary complications.
  • We therefore measured the levels of KL-6 and SP-D in sera from 128 patients (76 males and 52 females, mean age: 59 years) with hematological malignancies, including adult T-cell leukemia (ATL).
  • Indeed, high serum levels of KL-6 were closely related to the stage of ATL, while the serum SP-D was elevated in ATL patients with pulmonary infection.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / complications. Lung Diseases / blood. Lung Diseases / complications. Mucin-1 / blood. Pulmonary Surfactant-Associated Protein D / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Flow Cytometry. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19478465.001).
  • [ISSN] 1349-3329
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Pulmonary Surfactant-Associated Protein D
  •  go-up   go-down


7. Furukawa Y, Tara M, Izumo S, Arimura K, Osame M: HTLV-I viral escape and host genetic changes in the development of adult T cell leukemia. Int J Cancer; 2006 Jan 15;118(2):381-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-I viral escape and host genetic changes in the development of adult T cell leukemia.
  • In the pathogenesis of adult T cell leukemia (ATL), an oncogenetic role of the human T cell lymphotropic virus type I (HTLV-I) Tax protein, viral escape from the host immune system, and host genetic changes have been proposed as contributory factors.
  • We examined the premature stop codons in tax gene as one of the mutations that may lead to escape of HTLV-I from the cytotoxic T lymphocyte (CTL) response in HTLV-I carriers, to test whether a putative CTL escape mutant can emerge in the early stage of ATL development and whether HTLV-I infected cells with such a mutation can proliferate subsequently.
  • We also examined deletion of cyclin-dependent kinase inhibitor 4 (INK4) genes and mutation of p53 gene in combination with changes in the HTLV-I genome in acute type ATL to test whether host genetic changes promoted the malignant transformation of ATL cells that carry putative CTL escape mutations.
  • The premature stop codon in tax gene existed in many non-ATL HTLV-I carriers as a minor population but not in the commonest HTLV-I sequence of the individual.
  • There were cases who had a mutation or deletion in HTLV-I who also have either deletion of INK4 genes or mutation in p53 gene.
  • Our findings suggest that CTL escape mutation can occur at an early stage of ATL development, and that certain host genetic changes favor the development of the aggressive form of ATL.
  • [MeSH-major] Codon, Nonsense. Genes, pX / genetics. Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Cell Proliferation. Cell Survival. Cyclin-Dependent Kinase Inhibitor Proteins / genetics. Cyclin-Dependent Kinase Inhibitor Proteins / physiology. Genes, p53. HTLV-I Infections / complications. Humans. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16052518.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / Cyclin-Dependent Kinase Inhibitor Proteins
  •  go-up   go-down


8. Phillips AA, Shapira I, Willim RD, Sanmugarajah J, Solomon WB, Horwitz SM, Savage DG, Bhagat G, Soff G, Zain JM, Alobeid B, Seshan VE, O'Connor OA: A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer; 2010 Jul 15;116(14):3438-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score.
  • BACKGROUND: To define the clinicopathologic and prognostic features of patients with human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATLL) in North America, standard criteria were used to identify patients with ATLL.
  • Although the International Prognostic Index and Prognostic Index for peripheral T-cell lymphoma unspecified identified subsets of patients, these models were not completely predictive.
  • A recursive partitioning analysis was performed on the data, which successfully identified 3 prognostic categories based on Eastern Cooperative Oncology Group performance status, stage, age, and calcium level at diagnosis.
  • CONCLUSIONS: This series proposed a new prognostic model for patients with HTLV-1-associated ATLL and confirmed a poor outcome for these patients in North America.
  • [MeSH-major] Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. United States

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564100.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


9. Gualco G, Weiss LM, Barber GN, Bacchi CE: T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Hum Pathol; 2010 Sep;41(9):1238-44
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
  • The physiologic expression of the product of the proto-oncogene TCL1 (T-cell leukemia 1) is primarily restricted to early embryonic cells.
  • In nonneoplastic B cells, the expression of TCL1 is determined by the differentiation step with silencing at the germinal center stage.
  • It has been shown that TCL1 is a powerful B-cell oncogene, which has been implicated in the pathogenesis of various types of mature B-cell lymphomas.
  • There is no comparative information in the literature addressing the expression of TCL1 in pediatric and adult nodal diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.
  • We studied 55 cases of adult and pediatric diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma to analyze the phenotypic profile of these lymphomas, including TCL1 expression, and its relationship with clinical outcome in different age groups.
  • TCL1 was observed in 11 cases, 5 pediatric and 6 adult cases, all but one diffuse large B-cell lymphoma.
  • TCL1 positivity was predominantly found in germinal center phenotype diffuse large B-cell lymphoma.
  • Overall survival was worse in adult TCL1-positive cases than pediatric ones.
  • Primary mediastinal large B-cell lymphomas infrequently expressed TCL1 in both age groups.
  • [MeSH-major] Epstein-Barr Virus Infections / metabolism. Herpesvirus 4, Human / isolation & purification. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Mediastinal Neoplasms / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Female. Genes, myc. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Phenotype. Proto-Oncogene Proteins c-myc / genetics. Proto-Oncogene Proteins c-myc / metabolism. Survival Rate. Translocation, Genetic. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20382409.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / TCL1A protein, human
  •  go-up   go-down


10. Choi YL, Tsukasaki K, O'Neill MC, Yamada Y, Onimaru Y, Matsumoto K, Ohashi J, Yamashita Y, Tsutsumi S, Kaneda R, Takada S, Aburatani H, Kamihira S, Nakamura T, Tomonaga M, Mano H: A genomic analysis of adult T-cell leukemia. Oncogene; 2007 Feb 22;26(8):1245-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genomic analysis of adult T-cell leukemia.
  • Adult T-cell leukemia (ATL) is an intractable malignancy of CD4+ T cells that is etiologically associated with infection by human T-cell leukemia virus-type I.
  • Most individuals in the chronic stage of ATL eventually undergo progression to a highly aggressive acute stage.
  • To clarify the mechanism responsible for this stage progression, we isolated CD4+ cells from individuals in the chronic (n=19) or acute (n=22) stages of ATL and subjected them to profiling of gene expression with DNA microarrays containing >44,000 probe sets.
  • Changes in chromosome copy number were also examined for 24 cell specimens with the use of microarrays harboring approximately 50,000 probe sets.
  • Stage-dependent changes in gene expression profile and chromosome copy number were apparent.
  • Furthermore, expression of the gene for MET, a receptor tyrosine kinase for hepatocyte growth factor (HGF), was shown to be specific to the acute stage of ATL, and the plasma concentration of HGF was increased in individuals in either the acute or chronic stage.
  • HGF induced proliferation of a MET-positive ATL cell line, and this effect was blocked by antibodies to HGF.
  • [MeSH-major] Gene Expression Profiling. Genome, Human / genetics. Hepatocyte Growth Factor / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Proto-Oncogene Proteins / genetics. Receptors, Growth Factor / genetics
  • [MeSH-minor] Cell Line, Tumor. Gene Dosage. Genomics. Humans. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins c-met. Transcription, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909099.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


11. Sakai C, Murotani N: [Adult T-cell leukemia/lymphoma in a patient on hemodialysis-resistance to CHOP, but unexpected effect and remission achieved by sobuzoxane alone]. Gan To Kagaku Ryoho; 2010 Feb;37(2):347-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult T-cell leukemia/lymphoma in a patient on hemodialysis-resistance to CHOP, but unexpected effect and remission achieved by sobuzoxane alone].
  • The serum soluble IL-2 receptor was 47,500 U/mL, and HTLV-1 antibody was positive.
  • The pathological diagnosis was peripheral T-cell lymphoma, CD4(+).
  • He was clinically diagnosed as having an adult T-cell leukemia/lymphoma, lymphoma type, and clinical stage II.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Leukemia-Lymphoma, Adult T-Cell / complications. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Piperazines / therapeutic use. Renal Dialysis. Renal Insufficiency / complications

  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154500.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Piperazines; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; R1308VH37P / sobuzoxane; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Vonderheid EC, Pena J, Nowell P: Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging. Leuk Lymphoma; 2006 Sep;47(9):1841-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging.
  • In this retrospective study, quantitative Sézary cell counts were performed at presentation on 192 patients with erythrodermic cutaneous T-cell lymphoma (E-CTCL).
  • Per recommendation of the International Society of Cutaneous Lymphomas (ISCL), the impact on staging of using an absolute Sézary cell count of 1.0 K microL-1 or more as equivalent to lymph node involvement was investigated.
  • Of 132 patients with disease initially classified at stage III using the current TNM staging system, 25% were up staged to IVa, resulting in a clearer separation of associated survival curves between the stages.
  • Furthermore, the current ISCL definition of B0, B1 and B2 ratings were improved using Sézary cell count levels of < 1.0 K microL-1, > or = 1.0 - 4.99 K microL-1 and > or = 5.0 K microL-1, respectively.
  • [MeSH-major] Dermatitis, Exfoliative / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis. Sezary Syndrome / blood. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Female. Humans. Lymph Nodes. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064997.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


13. Beltran BE, Morales D, Quiñones P, Salas R, Castillo J: Analysis of prognostic factors in patients with adult T-cell leukemia/lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in patients with adult T-cell leukemia/lymphoma.
  • : 8575 Background: Adult T-cell leukemia/lymphoma (ATLL) is associated with human T-cell lymphotropic virus type-I (HTLV-1) described in Southern Japan, Europe, Caribbean and South America.
  • Diagnosis was based on clinical history and histological findings consistent with ATLL and either positive HTLV-1 serology or evidence of HTLV-1 integration.
  • In the univariate analysis, presence of B symptoms, ECOG performance status 2, clinical stage II or higher, elevated LDH level and bone marrow (BM) involvement were independent factors for survival with p<0.05.
  • The prognostic index for T-cell lymphoma (PIT) score was determined in 80 patients; 20 (25%), 17 (21%), 33 (41%) and 10 (13%) patients had scores of 0-1, 2, 3 and 4, respectively.
  • The IPI ant PIT scores, used for risk-stratification of aggressive B-cell and peripheral T-cell lymphomas, respectively, appear as good prognostic indicators for ATLL as well.
  • Further research is needed to better risk-stratify this unique lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962272.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Barbeau B, Mesnard JM: Does the HBZ gene represent a new potential target for the treatment of adult T-cell leukemia? Int Rev Immunol; 2007 Sep-Dec;26(5-6):283-304

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the HBZ gene represent a new potential target for the treatment of adult T-cell leukemia?
  • Links between human T-cell leukemia virus type 1 and adult T-cell leukemia (ATL) were first suspected in 1980.
  • Although the viral Tax protein is involved in the proliferation of the infected cells during the preleukemic stage, Tax expression is not systematically detected in primary leukemic cells.
  • [MeSH-major] Basic-Leucine Zipper Transcription Factors / genetics. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / metabolism. Leukemia-Lymphoma, Adult T-Cell / virology. Viral Proteins / genetics
  • [MeSH-minor] Cell Proliferation. Gene Expression Regulation, Viral. Gene Products, tax / genetics. Gene Products, tax / metabolism. Genes, pX. Genome, Viral. Humans. T-Lymphocytes / cytology. T-Lymphocytes / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027202.001).
  • [ISSN] 0883-0185
  • [Journal-full-title] International reviews of immunology
  • [ISO-abbreviation] Int. Rev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / Viral Proteins
  • [Number-of-references] 106
  •  go-up   go-down


15. Kobayashi R, Yamato K, Tanaka F, Takashima Y, Inada H, Kikuchi A, Kumagai MA, Sunami S, Nakagawa A, Fukano R, Fujita N, Mitsui T, Tsurusawa M, Mori T, Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group: Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer; 2010 Feb;54(2):212-5
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan.
  • BACKGROUND: Reports of non-anaplastic peripheral T-cell lymphoma (PTCL) in pediatric patients are relatively rare.
  • There were nine patients with PTCL, not otherwise specified (PTCL-NOS); ten with extranodal NK/T-cell lymphoma, nasal type; one with angioimmunoblastic T-cell lymphoma; and one with subcutaneous panniculitis-like T-cell lymphoma.
  • There were 12 patients with advanced stage disease (stages III and IV).
  • CONCLUSIONS: Generally, the outcome results of conventional chemotherapy for high-risk PTCL are poor in adult patients.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / epidemiology. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Japan / epidemiology. Male. Retrospective Studies. Stem Cell Transplantation. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19856396.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Park BB, Ryoo BY, Lee JH, Kwon HC, Yang SH, Kang HJ, Kim HJ, Oh SY, Ko YH, Huh JR, Lee SS, Nam EM, Park KW, Kim JH, Kang JH, Bang SM, Park S, Kim K, Park K, Suh C, Kim WS: Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2007 Apr;48(4):716-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.
  • The objective of this retrospective study was to investigate clinical features and treatment outcomes in patients with angioimmunoblastic T-cell lymphoma (AITL), data of which were collected over a 15-year period.
  • About half of the patients (46.2%) presented with poor performance status (ECOG > or = 2); 72.3% of patients belonged to high intermediate or high-risk of IPI and same proportion belonged to Class 2 of PIT (Prognostic index for PTCL-U), and most patients (95.4%) were diagnosed at an advanced stage.
  • [MeSH-major] Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Neovascularization, Pathologic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anthracyclines / pharmacology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Apr;48(4):645-6 [17454617.001]
  • (PMID = 17454629.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


17. Lee KW, Yun T, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK: First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma; 2006 Jul;47(7):1274-82
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.
  • Although most patients diagnosed with extranodal NK/T-cell lymphoma (NTCL) have localized disease, radiotherapy alone is unsatisfactory because of frequent systemic failure and conventional doxorubicin-based chemotherapy has low efficacy.
  • Radiotherapy was administered only to patients with Ann Arbor stage I/II that had not achieved complete remission (CR) or to those that developed local failure after completing chemotherapy.
  • Sixteen patients (group A) had nasal or upper aerodigestive tract localization (stage I/II) and 10 (group B) had extranasal or disseminated disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Etoposide / administration & dosage. Ifosfamide / administration & dosage. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. Methotrexate / administration & dosage. Prednisolone / administration & dosage
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Remission Induction. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923557.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 9PHQ9Y1OLM / Prednisolone; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL, Ryder LP, Ralfkiaer E: FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia; 2007 Dec;21(12):2512-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.
  • In solid tumours, high numbers of Tregs are associated with a poor prognosis.
  • In this study, skin biopsies from 86 patients with mycosis fungoides (MF) and cutaneous T-cell lymphoma (CTCL) unspecified were analysed for the expression of FOXP3 on tumour cells and tumour-infiltrating Tregs.
  • MF with early or infiltrated plaques had significantly higher numbers of FOXP3+ Tregs than CTCL unspecified or advanced MF with tumours or transformation to large cell lymphoma.
  • An analysis of all patients demonstrated that increasing numbers of FOXP3+ Tregs were associated with improved survival in both MF and CTCL unspecified.
  • In conclusion, our data indicate that the presence of FOXP3+ Tregs in CTCL is associated with disease stage and patient survival.
  • [MeSH-major] Forkhead Transcription Factors / analysis. Lymphocytes, Tumor-Infiltrating / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Mycosis Fungoides / pathology. Skin Neoplasms / pathology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Jurkat Cells / chemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Recombinant Fusion Proteins / analysis. Survival Analysis

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713545.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


19. Onesti MG, Mazzocchi M, De Leo A, Scuderi N: T-cell lymphoma presenting as a rapidly enlarging tumor on the lower eyelid. Acta Chir Plast; 2005;47(3):65-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoma presenting as a rapidly enlarging tumor on the lower eyelid.
  • Lymphoma or leukemia skin lesions as a secondary site of disease are quite common; however, to discover a cutaneous Hodgkin or non-Hodgkin lymphoma is very unusual.
  • To find a cutaneous T-cell lymphoma on the skin of the face is a rarity.
  • Because the condition is so rare and difficult to diagnose and treat, we report the case of a young man with a T-cell lymphoma with atypical and anaplastic cells on the lower eyelid.
  • Our case was clinically suggestive of a rapidly enlarging malignant lymphoma on the eyelid.
  • If the lymphomas are detected at an early stage the prognosis for survival is favorable.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Eyelids. Humans. Male. Prednisone / therapeutic use. Radiotherapy. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173513.001).
  • [ISSN] 0001-5423
  • [Journal-full-title] Acta chirurgiae plasticae
  • [ISO-abbreviation] Acta Chir Plast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


20. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, Kagami Y, Tsuzuki T, Kurokawa M, Ito K, Kawa K, Oshimi K, NK-cell Tumor Study Group: Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol; 2010 May;21(5):1032-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type.
  • BACKGROUND: Patients with natural killer (NK) cell neoplasms, aggressive NK cell leukemia (ANKL) and extranodal NK cell lymphoma, nasal type (ENKL), have poor outcome.
  • The purpose of this study is to draw a prognostic model of total NK cell neoplasms.
  • RESULTS: Complete remission rate for ENKL was 73% in stage I, but 15% in stage IV, which was consistent with that for ANKL (18%).
  • The prognosis of ENKL was better than that of ANKL (median survival 10 versus 1.9 months, P < 0.0001) but was comparable when restricted to stage IV cases (4.0 months, P = 0.16).
  • Multivariate analysis showed that four factors (non-nasal type, stage, performance status and numbers of extranodal involvement) were significant prognostic factors.
  • CONCLUSION: The current prognostic model successfully stratified patients with NK cell neoplasms with different outcomes.


21. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H, Tobias J, Li Y, Wolfe MS, Shachaf C, Felsher D, Blacklow SC, Pear WS, Aster JC: c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev; 2006 Aug 1;20(15):2096-109
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma.
  • Human acute T-cell lymphoblastic leukemias and lymphomas (T-ALL) are commonly associated with gain-of-function mutations in Notch1 that contribute to T-ALL induction and maintenance.
  • Starting from an expression-profiling screen, we identified c-myc as a direct target of Notch1 in Notch-dependent T-ALL cell lines, in which Notch accounts for the majority of c-myc expression.
  • In functional assays, inhibitors of c-myc interfere with the progrowth effects of activated Notch1, and enforced expression of c-myc rescues multiple Notch1-dependent T-ALL cell lines from Notch withdrawal.
  • This Notch1-mediated rescue is associated with the up-regulation of endogenous murine c-myc and its downstream transcriptional targets, and the acquisition of sensitivity to Notch pathway inhibitors.
  • Additionally, we show that primary murine thymocytes at the DN3 stage of development depend on ligand-induced Notch signaling to maintain c-myc expression.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2005 Aug 12;122(3):435-47 [16096062.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):881-8 [16056227.001]
  • [Cites] J Exp Med. 2005 Oct 17;202(8):1037-42 [16230473.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] J Exp Med. 1999 Oct 18;190(8):1039-48 [10523602.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):94-104 [15668164.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):314-22 [15665828.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):303-10 [15723053.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):311-8 [15723054.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):295-302 [15723055.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1278-81 [11062542.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):484-9 [11101851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Nat Immunol. 2001 Apr;2(4):307-15 [11276201.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5925-34 [11486031.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Genes Dev. 2002 Feb 1;16(3):295-300 [11825871.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):209-20 [16354692.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Immunity. 2006 Jan;24(1):53-64 [16413923.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):5106-19 [16365048.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:653-99 [11031250.001]
  • [Cites] Curr Biol. 1999 Nov 4;9(21):1255-8 [10556095.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3831-42 [10805726.001]
  • [Cites] Nature. 2000 May 18;405(6784):364-8 [10830967.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):197-206 [10882062.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):207-16 [10882063.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3337-48 [10880446.001]
  • [Cites] Curr Biol. 2000 Jun 29;10(13):R471-3 [10898989.001]
  • [Cites] Immunity. 2000 Jul;13(1):73-84 [10933396.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7505-15 [11003647.001]
  • [Cites] Dev Biol. 1999 Sep 1;213(1):33-53 [10452845.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Cell. 1999 Sep 17;98(6):779-90 [10499795.001]
  • [Cites] Immunity. 2002 Jun;16(6):869-79 [12121668.001]
  • [Cites] EMBO J. 2002 Sep 16;21(18):4820-30 [12234922.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Biochemistry. 2003 Jan 14;42(1):137-44 [12515548.001]
  • [Cites] Science. 2003 Feb 7;299(5608):887-90 [12574629.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2693-703 [12446444.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1071-7 [12730130.001]
  • [Cites] Cell Cycle. 2003 May-Jun;2(3):181-4 [12734418.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21232-9 [12644465.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):551-64 [12842084.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):841-6 [14574413.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):451-61 [14706337.001]
  • [Cites] Nat Immunol. 2004 Mar;5(3):247-53 [14985712.001]
  • [Cites] Nat Immunol. 2004 Apr;5(4):410-7 [15034575.001]
  • [Cites] Cell. 2004 May 14;117(4):515-26 [15137944.001]
  • [Cites] Immunity. 2004 May;20(5):611-22 [15142529.001]
  • [Cites] J Biol Chem. 2004 Jun 11;279(24):24986-93 [15067010.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9265-73 [15485896.001]
  • [Cites] EMBO J. 1988 Dec 1;7(12):3917-27 [3145200.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1665-9 [8453639.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 25;22(6):965-71 [8152928.001]
  • [Cites] Cell. 1994 Oct 7;79(1):143-56 [7923373.001]
  • [Cites] Mol Cell Biol. 1994 Dec;14(12):8292-303 [7969165.001]
  • [Cites] Cell. 1995 Oct 20;83(2):289-99 [7585946.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1683-8 [8643690.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1930-44 [8756350.001]
  • [Cites] Development. 1997 Feb;124(4):925-36 [9043073.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12274-9 [9356439.001]
  • [Cites] Nature. 1998 May 28;393(6683):382-6 [9620803.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):518-22 [10206645.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):522-5 [10206646.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):525-9 [10206647.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):215-7 [15738972.001]
  • [Cites] Annu Rev Immunol. 2005;23:945-74 [15771590.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):671-9 [15951812.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):663-70 [15951813.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):680-8 [15991363.001]
  • [ErratumIn] Genes Dev. 2007 Mar 1;21(5):625
  • (PMID = 16847353.001).
  • [ISSN] 0890-9369
  • [Journal-full-title] Genes & development
  • [ISO-abbreviation] Genes Dev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R56 CA092433; United States / NCI NIH HHS / CA / T32 CA 09140-31-35; United States / NCI NIH HHS / CA / R56 CA092433-06A1; United States / NCI NIH HHS / CA / R01 CA092433; United States / NCI NIH HHS / CA / T32 CA009140; None / None / / R01 CA092433-06A2; United States / NCI NIH HHS / CA / CA119130-01; United States / NCI NIH HHS / CA / R01 CA119130; United States / NCI NIH HHS / CA / P01 CA119070-01A19001; United States / NCI NIH HHS / CA / CA119070-01A19001; None / None / / R56 CA092433-06A1; United States / NCI NIH HHS / CA / R01 CA092433-06A2; United States / NCI NIH HHS / CA / R01 CA119130-01; United States / NCI NIH HHS / CA / P01 CA119070
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / Notch1 protein, mouse; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptor, Notch1
  • [Other-IDs] NLM/ PMC1536060
  •  go-up   go-down


22. Suzuki S, Uozumi K, Maeda M, Yamasuji Y, Hashimoto S, Komorizono Y, Owatari S, Tokunaga M, Haraguchi K, Arima N: Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rejection. Int J Hematol; 2006 Jun;83(5):429-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rejection.
  • A liver allograft recipient developed acute-type adult T-cell leukemia (ATL) during tacrolimus treatment, 2 years after undergoing transplantation for subacute fulminant hepatitis.
  • Both donor and recipient were asymptomatic carriers of human T-cell lymphotropic virus type I (HTLV-I), but the ATL cells originated from the recipient.
  • Liver biopsies showed CD4+ ATL cell infiltration at the onset of ATL but not at the terminal stage.
  • Moreover, Southern blotting revealed clonal integration of HTLV-I into the host genome of lymphoma cells at onset but not at the terminal stage.
  • [MeSH-major] Hepatitis / complications. Leukemia-Lymphoma, Adult T-Cell / etiology. Liver Failure, Acute / complications. Liver Transplantation. Living Donors


23. Sudhakar N, Nancy NK, Rajalekshmy KR, Rajkumar T: Diversity of T-cell receptor gene rearrangements in South Indian patients with common acute lymphoblastic leukemia. Iran J Immunol; 2009 Sep;6(3):141-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diversity of T-cell receptor gene rearrangements in South Indian patients with common acute lymphoblastic leukemia.
  • BACKGROUND: Precursor B-Acute Lymphoblastic Leukemia (precursor B-ALL) occurs due to the uncontrolled proliferation of B-lymphoid precursors arrested at a particular stage of B-cell development.
  • OBJECTIVE: This study was aimed to examine the diversity of T-cell receptor Gamma (TCRG) and T-cell receptor Delta (TCRD) gene rearrangements in South Indian Common-ALL patients.
  • [MeSH-major] Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Genetic Variation. Humans. India. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801787.001).
  • [ISSN] 1735-1383
  • [Journal-full-title] Iranian journal of immunology : IJI
  • [ISO-abbreviation] Iran J Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


24. Arima N, Sugiyama T: [Pentostatin treatment for a patient with chronic type adult T-cell leukemia undergoing hemodialysis]. Rinsho Ketsueki; 2005 Nov;46(11):1191-5
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pentostatin treatment for a patient with chronic type adult T-cell leukemia undergoing hemodialysis].
  • We present a patient with chronic adult T-cell leukemia, whose white blood cell count exceeded 100 X 10(9)/l, and end-stage renal disease, receiving long-term thrice-weekly dialysis.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Kidney Failure, Chronic / complications. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Pentostatin / administration & dosage. Renal Dialysis

  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440802.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 395575MZO7 / Pentostatin
  •  go-up   go-down


25. Mansur MB, Emerenciano M, Brewer L, Sant'Ana M, Mendonça N, Thuler LC, Koifman S, Pombo-de-Oliveira MS: SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome. Leuk Lymphoma; 2009 Aug;50(8):1318-25
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome.
  • SIL-TAL1 fusion gene and the ectopic expression of HOX11L2 are common molecular abnormalities in T-cell acute lymphoblastic leukemia (T-ALL).
  • The most frequent maturation stage was T-IV (40.1%), and 30.7% of cases were CD10(+).
  • [MeSH-major] Homeodomain Proteins / analysis. Oncogene Proteins, Fusion / blood. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brazil / epidemiology. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunophenotyping. Infant. Infant, Newborn. Kaplan-Meier Estimate. Male. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562638.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 0 / SIL-TAL1 fusion protein, human; 0 / TLX3 protein, human
  •  go-up   go-down


26. Lozzi GP, Massone C, Citarella L, Kerl H, Cerroni L: Rimming of adipocytes by neoplastic lymphocytes: a histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol; 2006 Feb;28(1):9-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rimming of adipocytes by neoplastic lymphocytes: a histopathologic feature not restricted to subcutaneous T-cell lymphoma.
  • Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cytotoxic T-cell lymphoma of the skin presenting with histopathologic features simulating those of a lobular panniculitis.
  • The presence of neoplastic T-lymphocytes forming a rim around the individual fat cells in the subcutaneous lobules, so-called "rimming" of adipocytes, is considered a characteristic morphologic feature of this type of cutaneous lymphoma.
  • In this study we reviewed a series of 45 biopsy specimens of primary and secondary cutaneous B- and T-cell lymphomas and one of myeloid leukemia involving the subcutaneous tissues and showing rimming of adipocytes (subcutaneous panniculitis-like T-cell lymphoma: n = 16; mycosis fungoides, tumor stage: n = 3; aggressive epidermotropic CD8(+) T-cell lymphoma: n = 2; cutaneous gamma/delta T-cell lymphoma: n = 4; extranodal NK/T-cell lymphoma, nasal type: n = 4; cutaneous medium-large pleomorphic T-cell lymphoma, NOS: n = 5; CD4(+)/CD56(+) hematodermic neoplasm (blastic NK-cell lymphoma): n = 7; secondary cutaneous large B-cell lymphoma: n = 3; secondary cutaneous lymphoplasmacytic lymphoma: n = 1; specific cutaneous manifestations of acute myelogenous leukemia: n = 1).
  • We could demonstrate that rimming of adipocytes by neoplastic cells can be recognized not only in subcutaneous panniculitis-like T-cell lymphoma, but also in several different entities of malignant lymphoma with skin involvement.
  • Rimming of adipocytes should not be considered specific of subcutaneous panniculitis-like T-cell lymphoma.
  • [MeSH-major] Adipocytes / pathology. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology. Skin Neoplasms / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Gene Rearrangement. Genes, T-Cell Receptor gamma / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Panniculitis / metabolism. Panniculitis / pathology. Receptors, Antigen, T-Cell, gamma-delta / genetics. Receptors, Antigen, T-Cell, gamma-delta / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456318.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


27. Uzurov-Dinić V, Savić A, Lazarević T, Cemerikić-Martinović V, Agić D, Popović S: [Prognostic factors in patients with diffuse large B-cell lymphoma]. Med Pregl; 2009 Mar-Apr;62(3-4):171-6
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in patients with diffuse large B-cell lymphoma].
  • Diffuse large B-cell lymphoma is an aggressive type of lymphoma, potentially curable, with heterogeneous prognosis.
  • The retrospective study was done in 50 patients with diffuse large B-cell lymphoma.
  • The following parameters were investigated: demographic (age, sex), clinical (time to diagnosis, B symptoms, clinical stage), laboratory (erythrocyte sedimentarion rate, haemoglobin, lactate dehydrogenase, albumine), standard and revised international prognostic index, and immunohystochemical parameters, cluster designation 20, B-cell-2, and Ki67 expression.
  • The majority of patients had advanced disease: B symptoms in 76%, III and IV stage in 78%, increased lactate dehydrogenase in 74%, high risk standard international prognostic index in 62% of patients.
  • B-cell leukemia/lymphoma 2 expression was found in 57%, and high Ki67 in 62% of patients.
  • Our results have shown that international prognostic index, and complete remission status have prognostic significance in diffuse large B-cell lymphomas.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623849.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


28. Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thiéblemont C, Gaulard P, Marin B, Gachard N, Bordessoule D, Hermine O: L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol; 2009 Jan;20(1):110-6
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
  • BACKGROUND: Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are highly aggressive diseases with a poor outcome.
  • Thirteen patients were in relapse and/or refractory and 10 patients were at stage IV.
  • CONCLUSION: These data, although retrospective, confirm the excellent activity of L-asparaginase-containing regimens in refractory extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia.
  • First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia should be tested in prospective trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701429.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase
  • [Number-of-references] 26
  •  go-up   go-down


29. Pulte D, Olson KE, Broekman MJ, Islam N, Ballard HS, Furman RR, Olson AE, Marcus AJ: CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia. J Transl Med; 2007 May 04;5:23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia.
  • BACKGROUND: Chronic lymphocytic leukemia (CLL) is characterized by accumulation of mature appearing lymphocytes and is rarely complicated by thrombosis.
  • RESULTS: Functional assays demonstrated that ADPase and ATPase activities were much higher in CLL cells than in total lymphocytes from the normal population on a per cell basis (p-value < 0.00001).
  • CD39 activity was elevated in stage 0-2 CLL compared to stage 3-4 (p < 0.01).
  • Enzyme activity is higher in earlier stages of CLL and decreased enzyme activity may be associated with worsening disease.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologia (Budap). 2000;30(1):51-4 [10841326.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Mol Med. 2000 Jul;6(7):591-603 [10997340.001]
  • [Cites] J Histochem Cytochem. 2002 Apr;50(4):549-56 [11897808.001]
  • [Cites] Nat Med. 2002 Apr;8(4):358-65 [11927941.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4087-93 [12010811.001]
  • [Cites] Am J Hematol. 2002 Nov;71(3):208-10 [12410577.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):2962-70 [12626548.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Apr;305(1):9-16 [12649347.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1865-8 [12685846.001]
  • [Cites] Ann Hematol. 2004 Jan;83(1):61-3 [12961031.001]
  • [Cites] J Clin Invest. 2004 May;113(10):1440-6 [15146241.001]
  • [Cites] J Clin Invest. 1980 Nov;66(5):979-86 [6776148.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1398-401 [2646007.001]
  • [Cites] J Immunol. 1991 Apr 1;146(7):2235-44 [1672348.001]
  • [Cites] J Clin Invest. 1991 Nov;88(5):1690-6 [1939654.001]
  • [Cites] Am J Hematol. 1993 Feb;42(2):221-4 [8438883.001]
  • [Cites] Am J Gastroenterol. 1995 Apr;90(4):635-7 [7717324.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1052-7 [7675049.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Haematol. 1997 Jan;96(1):111-6 [9012696.001]
  • [Cites] Blood. 1997 Feb 1;89(3):919-28 [9028323.001]
  • [Cites] J Clin Invest. 1997 Mar 15;99(6):1351-60 [9077545.001]
  • [Cites] Am J Physiol. 1997 Sep;273(3 Pt 1):C973-87 [9316419.001]
  • [Cites] J Clin Invest. 1998 May 1;101(9):1851-9 [9576748.001]
  • [Cites] FEBS Lett. 1998 Jul 3;430(3):227-30 [9688544.001]
  • [Cites] Blood. 1999 Jan 15;93(2):624-31 [9885225.001]
  • [Cites] Br J Neurosurg. 1998 Aug;12(4):373-6 [10070435.001]
  • [Cites] Int Immunol. 1999 May;11(5):739-44 [10330279.001]
  • [Cites] Blood. 1999 Jul 15;94(2):448-54 [10397712.001]
  • [Cites] Thromb Res. 2005;115(1-2):59-64 [15567454.001]
  • [Cites] J Appl Physiol (1985). 2005 Apr;98(4):1414-9 [15772061.001]
  • [Cites] Semin Thromb Hemost. 2005 Apr;31(2):234-46 [15852226.001]
  • [Cites] Thromb Res. 2005;116(3):199-206 [15935828.001]
  • [Cites] J Thromb Thrombolysis. 2005 Apr;19(2):115-22 [16052302.001]
  • [Cites] Biochemistry. 2000 Jun 13;39(23):6936-43 [10841775.001]
  • (PMID = 17480228.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL046403; United States / NINDS NIH HHS / NS / R01 NS041462; United States / NHLBI NIH HHS / HL / R01 HL047073; United States / NHLBI NIH HHS / HL / HL 46403; United States / NHLBI NIH HHS / HL / R37 HL047073; United States / NHLBI NIH HHS / HL / HL 47073; United States / NINDS NIH HHS / NS / NS 41462
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 61D2G4IYVH / Adenosine Diphosphate; EC 3.6.1.5 / Apyrase; EC 3.6.1.5 / CD39 antigen
  • [Other-IDs] NLM/ PMC1885243
  • [General-notes] NLM/ Original DateCompleted: 20070813
  •  go-up   go-down


30. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG: Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant; 2008 Jul;14(7):741-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
  • The peripheral T cell lymphomas (PTCL) carry a worse prognosis compared to B cell non-Hodgkin lymphoma.
  • There is no uniform standard therapy for PTCL, and autologous hematopoietic cell transplant (AHCT) is often offered as consolidation in first remission or at relapse because of the poor outcomes with conventional therapy.
  • Fifty-three cases were identified consisting of systemic anaplastic large cell (n = 18), PTCL unspecified (n = 17), angioimmunoblastic (n = 9), nasal type extranodal NK/T (n = 7), hepatosplenic (n = 2), and adult T cell leukemia/lymphoma (n = 1).
  • Histology, age, sex, stage, B symptoms, bone marrow involvement, and duration of first response did not significantly affect PFS or OS.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol J. 2004;5(4):304-11 [15297846.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):443-50 [17589529.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3334-41 [7538824.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Bone Marrow Transplant. 1999 Jul;24(2):153-61 [10455343.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):711-6 [11360110.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):978-85 [12648067.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11 [16785059.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Ann Hematol. 2007 Jun;86(6):435-42 [17256144.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):32-8 [17598836.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(3):239-43 [17530000.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1067-74 [17640855.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • (PMID = 18541192.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA049605-15; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / P01 CA049605-15
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS232367; NLM/ PMC2980839
  •  go-up   go-down


31. Babusikova O, Stevulova L, Fajtova M: Immunophenotyping parameters as prognostic factors in T-acute leukemia patients. Neoplasma; 2009;56(6):508-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping parameters as prognostic factors in T-acute leukemia patients.
  • The main aim of this study represents the extension of our studies using multiparametric flow cytometry analysis for exact definition of membrane and intracellular (cytoplasmic and nuclear) markers of acute leukemia cells of T-phenotype.
  • The study of blasts of each patient with all available monoclonal antibodies targeted to T-cell differential antigens and against possible marker coexistence from different lineages has been performed.
  • The main aim was concerned to more proper T-ALL diagnosis and stage definition and identification of the prognostic factors and the useful markers for the follow-up of T-ALL in remission.
  • New knowledge of the T-cell maturation stages of hematopoietic cells in bone marrow and thymus has been applied, as each T-acute leukemia clone is representative of one blocked stage through maturation.
  • Patients with more favorable prognosis (i. e. those of cortical stage) could have been already differentiated at diagnosis from those, allocated to pro-T stage, with very immature phenotypes and of an unfavorable clinical course.
  • The patients were either completely unresponsive to therapy or because of persistent MRD during continuation therapy, indicated for allogeneic hematopoietic stem-cell transplant.
  • The results have been discussed with similar the most relevant immunophenotypic results of others and mainly with gene-expressing profiling associated with a significantly worse clinical outcome.
  • [MeSH-major] Antigens, CD / immunology. Antigens, Differentiation, T-Lymphocyte / immunology. Biomarkers, Tumor / immunology. HLA-DR Antigens / analysis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm, Residual / immunology. Phenotype. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728759.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / HLA-DR Antigens
  •  go-up   go-down


32. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol; 2009 Nov 10;27(32):5410-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
  • PURPOSE Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors.
  • On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated.
  • PATIENTS AND METHODS The initial cohort was limited to patients with cutaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sézary syndrome, who had received no more than two prior cytotoxic regimens.
  • These patients had undergone a median of four prior treatments, and 62 patients (87%) had advanced-stage disease (stage IIB, n = 15; stage III, n= 6; or stage IV, n = 41).
  • [MeSH-major] Depsipeptides / therapeutic use. Histone Deacetylase Inhibitors / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / pharmacokinetics. Antibiotics, Antineoplastic / therapeutic use. Area Under Curve. Fatigue / chemically induced. Female. Humans. Leukemia / chemically induced. Male. Metabolic Clearance Rate. Middle Aged. Nausea / chemically induced. Thrombocytopenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 1995 Jul;133(1):6-12 [7669641.001]
  • [Cites] Ann Intern Med. 1994 Oct 15;121(8):592-602 [8085692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6791-6 [9618491.001]
  • [Cites] Exp Cell Res. 1998 May 25;241(1):126-33 [9633520.001]
  • [Cites] J Am Acad Dermatol. 1999 Mar;40(3):418-25 [10071312.001]
  • [Cites] J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):914-24 [10365922.001]
  • [Cites] Biol Pharm Bull. 2005 Jan;28(1):124-9 [15635176.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3697-702 [15738394.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):798-812 [15841167.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):428-34 [16112348.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3762-73 [16778104.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):30-9 [17464244.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):854-9 [17638728.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Apr 1;865(1-2):153-8 [18342585.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] Clin Lymphoma Myeloma. 2008 Aug;8(4):249-52 [18765314.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1496-503 [19228751.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6 [10922406.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):718-28 [11895901.001]
  • [Cites] Leuk Lymphoma. 2002 Jun;43(6):1297-302 [12152999.001]
  • [Cites] J Exp Ther Oncol. 2002 Nov-Dec;2(6):325-32 [12440223.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):13-8 [12892709.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Dec;17(6):1367-89, viii [14710890.001]
  • [Cites] Curr Pharm Des. 2004;10(19):2289-98 [15279609.001]
  • [Cites] Cancer Treat Rep. 1979 Apr;63(4):725-8 [445521.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):372-82 [3408055.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Lancet. 1991 Feb 2;337(8736):268-9 [1671113.001]
  • [Cites] JAMA. 1992 Mar 11;267(10):1354-8 [1740857.001]
  • [Cites] J Antibiot (Tokyo). 1994 Mar;47(3):301-10 [7513682.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5705-8 [8650156.001]
  • (PMID = 19826128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Depsipeptides; 0 / Histone Deacetylase Inhibitors; CX3T89XQBK / romidepsin
  • [Other-IDs] NLM/ PMC2773225
  •  go-up   go-down


33. Lin HN, Liu CY, Hong YC, Pai JT, Yang CF, Yu YB, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Tzeng CH, Chen PM: Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. Leuk Lymphoma; 2010 Dec;51(12):2208-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis.
  • Factors associated with overall survival (OS) were determined by statistical methods.
  • Among all patients, 67.7% were Ann Arbor stage III or IV, 58.1% presented with B symptoms, 48.4% had hypoalbuminenia (<35 g/L), and 63.3% had elevated lactate dehydrogenase (LDH) at diagnosis.
  • In multivariate analysis, initial presentation with fever (p = 0.035), advanced stage (p = 0.024), and failure to achieve CR (p = 0.029) were independent adverse factors associated with poorer OS.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Taiwan / epidemiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2011 Jan;52(1):1-2 [21133725.001]
  • (PMID = 21054150.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. El Weshi A, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y, Bazarbashi S, Maghfoor I: T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma; 2007 Sep;48(9):1764-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature.
  • T-cell/histiocyte-rich B-cell lymphoma (TC/HRBCL) is a rare subtype of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with characteristic morphologic and immunophenotypic features, often misdiagnosed as Hodgkin's lymphoma and peripheral T-cell lymphoma.
  • We retrospectively reviewed all patients diagnosed and managed at our institution between 1995 and 2004 diagnosed with T-cell-rich-B-cell lymphoma by WHO criteria.
  • Stage distribution was I - II in 21 patients, and III - IV in 40.
  • It has an aggressive course and poor outcome; with most of patients presenting with advanced disease stage together with high IPI score.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Salvage Therapy. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Sep;48(9):1670-1 [17786700.001]
  • (PMID = 17786712.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  •  go-up   go-down


35. Borovecki A, Korać P, Nola M, Ivanković D, Jaksić B, Dominis M: Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3. Croat Med J; 2008 Oct;49(5):625-35
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
  • AIM: To define prognostic significance of B-cell differentiation genes encoding proteins and BCL2 and BCL6 gene abnormalities in diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern.
  • METHODS: In 53 patients with diffuse large B-cell lymphoma and 20 patients with follicular lymphoma grade 3 with >75% follicular growth pattern the following was performed:.
  • 2) subclassification into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) groups according to the results of protein expression;.
  • 3) detection of t(14;18)(q32;q21)/IgH-BCL2 and BCL6 abnormalities by fluorescent in situ hybridization in diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern as well as in GCB and ABC groups; and 4) assessment of the influence of the analyzed characteristics and clinical prognostic factors on overall survival.
  • RESULTS: Only BCL6 expression was more frequently found in follicular lymphoma grade 3 with >75% follicular growth pattern than in diffuse large B-cell lymphoma (P=0.030).
  • There were no differences in BCL2 and BCL6 gene abnormalities between diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern.
  • Diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern patients were equally distributed in GCB and ABC groups. t(14;18)(q32;q21) was more frequently recorded in GCB group, and t(14;18)(q32;q21) with BCL2 additional signals or only BCL2 and IgH additional signals in ABC group (P=0.004).
  • There was no overall survival difference between the diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern patients, however, GCB group had longer overall survival than ABC group (P=0.047).
  • CONCLUSION: Diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern patients have very similar characteristics and their prognosis is more influenced by protein expression of B-cell differentiation stage genes than by tumor cells growth pattern, BCL2 and BCL6 abnormalities, and International Prognostic Index.
  • [MeSH-major] Biomarkers, Tumor / genetics. DNA-Binding Proteins / genetics. Interleukin-6 / genetics. Lymphoma, Follicular / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Neoplastic. Genetic Markers. Humans. Immunohistochemistry. Male. Middle Aged. Neprilysin / genetics. Predictive Value of Tests. Prognosis. Syndecan-1 / genetics

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Arch Pathol Lab Med. 2004 Aug;128(8):863-8 [15270618.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115(6):862-7 [11392883.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1136-43 [11830458.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jan 15;132(2):125-32 [11850073.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2285-90 [11895757.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] Blood. 2002 May 15;99(10):3806-12 [11986240.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Histopathology. 2002 Nov;41(5):414-20 [12405909.001]
  • [Cites] Histopathology. 2002 Dec;41(6):482-509 [12460202.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]
  • [Cites] Blood. 2003 Jan 1;101(1):78-84 [12393466.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1149-54 [12529293.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):722-8 [12576441.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2363-7 [12424193.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):36-42 [12838297.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):481-90 [15277222.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3498-506 [15337798.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Blood. 2005 Jan 1;105(1):301-7 [15345589.001]
  • [Cites] Int J Hematol. 2005 Jan;81(1):48-57 [15717689.001]
  • [Cites] Haematologica. 2005 Mar;90(3):341-7 [15749666.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):116-23 [15894922.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1058-63 [15815725.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1067-73 [16006802.001]
  • [Cites] Leuk Lymphoma. 2005 May;46(5):693-701 [16019506.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1113-20 [15920553.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1164-74 [15855278.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6351-7 [16155019.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3383-5 [16091454.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] Hum Pathol. 2006 May;37(5):528-33 [16647949.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):805-12 [17327602.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] Blood. 2007 Jul 1;110(1):29-36 [17360935.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):433-7 [17762566.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • (PMID = 18925696.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Genetic Markers; 0 / Interleukin-6; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Syndecan-1; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC2582355
  •  go-up   go-down


36. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol; 2010 Mar;34(3):327-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
  • B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL).
  • The clinical and pathologic spectrum of this rare entity, including comparison to other high-grade B-cell neoplasms, has not been well defined.
  • Six patients had a history of grade 1 to 2 follicular lymphoma; review of the prior biopsy specimens in 2 of 5 cases revealed blastoid morphology.
  • Eighteen patients had Ann Arbor stage 3 or 4 disease and all had elevated serum lactate dehydrogenase (LDH) levels at presentation.
  • Twelve DHL cases (60%) were classified as B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL, 7 cases (35%) as DLBCL, not otherwise specified, and 1 case as B-LBL.
  • DHL is a high-grade B-cell neoplasm with a poor prognosis, resistance to multiagent chemotherapy, and clinical and pathologic features distinct from other high-grade B-cell neoplasms.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Genes, Immunoglobulin Heavy Chain. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Terminology as Topic. Time Factors. Treatment Outcome. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):525-34 [10757399.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1960-6 [11069032.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):52-4 [11120335.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):610-3 [12708908.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):474-9 [15239399.001]
  • [Cites] Blood. 1983 Nov;62(5):1142-6 [6605167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Am J Clin Pathol. 1986 May;85(5):636-40 [3486584.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] N Engl J Med. 1988 May 26;318(21):1373-8 [3285208.001]
  • [Cites] Oncogene. 1988 May;2(5):431-5 [3131717.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1454-9 [2509518.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Oncogene. 1991 Jan;6(1):145-8 [1992441.001]
  • [Cites] Leukemia. 1991 Jan;5(1):83-7 [1999960.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Ann Hematol. 1991 Nov;63(5):282-7 [1958753.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):101-4 [1554791.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leukemia. 1994 Apr;8(4):560-3 [8152251.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):87-94 [8019967.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):414-23 [15852472.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1490-6 [16224216.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2313-23 [16193090.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):52-6 [17074591.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1061-4 [17182663.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):157-66 [18089500.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1593-607 [18753947.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):716-25 [19120369.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 20118770.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA076404; United States / NIGMS NIH HHS / GM / T32 GM074897; United States / NIGMS NIH HHS / GM / T32 GM074897-07
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS305320; NLM/ PMC3152212
  •  go-up   go-down


37. Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT: Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A; 2005 Apr 26;102(17):6068-73
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia.
  • We have created a stable transgenic rag2-EGFP-mMyc zebrafish line that develops GFP-labeled T cell acute lymphoblastic leukemia (T-ALL), allowing visualization of the onset and spread of this disease.
  • These T cell leukemias are clonally aneuploid, can be transplanted into irradiated recipient fish, and express the zebrafish orthologues of the human T-ALL oncogenes tal1/scl and lmo2, thus providing an animal model for the most prevalent molecular subgroup of human T-ALL.
  • Thus, we have created a conditional transgene in which the EGFP-mMyc oncogene is preceded by a loxed dsRED2 gene and have generated stable rag2-loxP-dsRED2-loxP-EGFP-mMyc transgenic zebrafish lines, which have red fluorescent thymocytes and do not develop leukemia.
  • Transgenic progeny from one of these lines can be induced to develop T-ALL by injecting Cre RNA into one-cell-stage embryos, demonstrating the utility of the Cre/lox system in the zebrafish and providing an essential step in preparing this model for chemical and genetic screens designed to identify modifiers of Myc-induced T-ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. ZFIN: Data: Gene Expression .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Development. 1996 Dec;123:1-36 [9007226.001]
  • [Cites] Immunogenetics. 2000 Sep;51(11):915-23 [11003385.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Dec;29(4):371-7 [11066085.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):12965-9 [11087852.001]
  • [Cites] Genesis. 2001 Apr;29(4):156-62 [11309848.001]
  • [Cites] Nucleic Acids Res. 2001 Jun 1;29(11):E53-3 [11376165.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1495-504 [11587205.001]
  • [Cites] Curr Biol. 2001 Oct 2;11(19):1481-91 [11591315.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7447-52 [11704876.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):135-40 [12006978.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Blood. 2002 Aug 1;100(3):991-7 [12130513.001]
  • [Cites] Mech Dev. 2002 Sep;117(1-2):243-8 [12204264.001]
  • [Cites] Science. 2003 Feb 7;299(5608):887-90 [12574629.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):176-81 [12619103.001]
  • [Cites] Nucleic Acids Res. 2003 Apr 15;31(8):e44 [12682379.001]
  • [Cites] Leukemia. 2003 May;17(5):887-93 [12750702.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):274-80 [14582078.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Nat Biotechnol. 2004 May;22(5):595-9 [15097998.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 11;101(19):7369-74 [15123839.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] N Engl J Med. 1987 Jan 8;316(2):79-84 [3537802.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1035-48 [2598259.001]
  • [Cites] Science. 1990 Jun 22;248(4962):1517-23 [2360047.001]
  • [Cites] Leukemia. 1991 Oct;5(10):839-40 [1961018.001]
  • [Cites] Science. 1994 Jul 1;265(5168):103-6 [8016642.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3105-12 [7949183.001]
  • [Cites] Blood. 1995 May 1;85(9):2321-30 [7727766.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2424-33 [9694806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):407-12 [15630097.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3278-85 [15618471.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3497-502 [10737801.001]
  • (PMID = 15827121.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Databank-accession-numbers] PIR/ AF398514
  • [Grant] United States / NCI NIH HHS / CA / P01 CA068484; United States / NCI NIH HHS / CA / P30 CA006516; United States / NCI NIH HHS / CA / CA-06516; United States / NCI NIH HHS / CA / CA-68484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / Genetic Markers; 0 / Nuclear Proteins; 0 / RAG2 protein, human; 0 / Rag2 protein, mouse; 0 / V(D)J recombination activating protein 2; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; 149137-54-2 / Lox protein, mouse; EC 1.4.3.13 / Protein-Lysine 6-Oxidase; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC1087915
  •  go-up   go-down


38. Huang Q, Su X, Ai L, Li M, Fan CY, Weiss LM: Promoter hypermethylation of multiple genes in gastric lymphoma. Leuk Lymphoma; 2007 Oct;48(10):1988-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation of multiple genes in gastric lymphoma.
  • Aberrant hypermethylation of CpG islands in the promoter region of tumor suppressor and other important genes in neoplastic cells of lymphoma has been demonstrated to be one of the mechanisms for epigenetic loss of gene function.
  • In this study, we analyzed promoter hypermethylation of the following genes in 49 cases of primary gastric lymphoma (PGL): ATM, p16INK4a(CDKN2A), hMLH1, MGMT, DAPK, and CDH1(ECAD).
  • The PGL cases studied included 26 (53%) cases of diffuse large B-cell lymphoma (DLBCL), 12 (25%) cases of extranodal marginal zone lymphoma (MZL), 7 (14%) cases of MZL with large cell transformation (MZL/DLBCL), 1 (2%) case of follicular lymphoma (FL), one (2%) case of Burkitt-like lymphoma (BL), one case (2%) of lymphoplasmacytic lymphoma (LPL) and one case (2%) of peripheral T-cell lymphoma.
  • Of 37 PGL cases, 19 cases had extragastric involvement at the time of resection, indicating relatively higher stage disease.
  • [MeSH-major] DNA Methylation. Gene Expression Regulation, Neoplastic. Lymphoma / genetics. Promoter Regions, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Base Sequence. DNA Damage. DNA Repair. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Molecular Sequence Data


39. Maha A, Gan GG, Koh CL: Phenotype and TCR-gamma gene rearrangements in a Malaysian cohort of T-cell leukaemia/lymphoma cases. Hematology; 2010 Dec;15(6):382-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotype and TCR-gamma gene rearrangements in a Malaysian cohort of T-cell leukaemia/lymphoma cases.
  • Discrete stages of T-cell differentiation are simplified to four stages (pro-, pre-, cortical and mature-T cell) and used in the classification of T-cell leukaemia.
  • HLA-DR has been reported to be expressed in immature T-cell acute lymphoblastic leukemia (ALL) and also confer a poorer treatment outcome.
  • Simultaneously, the genotype goes through distinct pattern changes due to rearrangement of T-cell receptor (TCR) genes.
  • We identified a subset within Pro-T and Pre-T cell cases distinguished by the expression of HLA-DR.
  • We also observed a higher incidence of mediastinal mass (67%) in the HLA-DR-subgroup in the Pre-T stage.
  • These characteristics may be useful as markers to further refine staging of T-cell ALL and determine prognosis.
  • [MeSH-major] Gene Rearrangement, T-Lymphocyte. Leukemia-Lymphoma, Adult T-Cell / pathology. Receptors, Antigen, T-Cell, gamma-delta / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / analysis. Biomarkers. Cell Differentiation. Child. Child, Preschool. Female. Genes, T-Cell Receptor / genetics. HLA-DR Antigens. Humans. Leukemia, T-Cell / classification. Leukemia, T-Cell / genetics. Leukemia, T-Cell / pathology. Malaysia. Male. Middle Aged. Phenotype. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21114900.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers; 0 / HLA-DR Antigens; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


40. Pan Y, Li GD, Liu WP, Zhang WY, Tang Y, Li FY: [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients]. Zhonghua Bing Li Xue Za Zhi; 2009 Dec;38(12):810-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
  • OBJECTIVE: To study the clinicopathologic features, immunohistochemical findings and prognosis of precursor lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL).
  • The pathologic findings were correlated with Ann Arbor tumor stage, Ki-67 index, other clinical parameters (including mediastinum/bone marrow involvement, hepato-splenomegaly, age and gender of the patients) and the survival data.
  • The cases were categorized into three groups according to the immunohistochemical findings, as follows: precursor T-cell, precursor B-cell and undefined.
  • Ninety-one cases (85.8%) were in stage III or IV at diagnosis.
  • Patients older than 25 years and those presented in stage III or IV suggested a poor prognosis (P = 0.049 and 0.001, respectively).
  • Twenty-one patients (72.4%) were in stage III or IV at diagnosis.
  • The prognostic criteria include age of older than 25 years and a classification of stage III or IV disease.
  • [MeSH-major] Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. DNA Nucleotidylexotransferase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Bone Marrow / pathology. Child. Child, Preschool. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Young Adult


41. Riz I, Hawley RG: G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia. Oncogene; 2005 Aug 25;24(36):5561-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia.
  • The HOX11/TLX1 homeobox gene is aberrantly expressed in a subset of T-cell acute lymphoblastic leukemia (T-ALL).
  • Here, we employed oligonucleotide microarrays to compare the expression profiles of the K3P and Sil leukemic cell lines originating from patients with HOX11+ T-ALL to that of Jurkat cells, which originated from a distinct subtype of T-ALL (TAL1+).
  • To distinguish potential HOX11 target genes from those characteristic of the stage of HOX11 leukemic arrest, we also performed gene expression analysis on Jurkat cells, genetically engineered to express exogenous HOX11.
  • The resulting HOX11 gene expression signature, which was validated for representative signaling pathways by transient transfection of reporter constructs, was characterized by elevated expression of transcriptional programs involved in cell proliferation, including those regulated by E2F, c-Myc and cAMP response element-binding protein.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1990 Jan 12;60(1):167-76 [2153055.001]
  • [Cites] Science. 1991 Jul 5;253(5015):79-82 [1676542.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7030-7 [9819390.001]
  • [Cites] Nature. 1998 Nov 12;396(6707):184-6 [9823900.001]
  • [Cites] Oncogene. 1998 Nov 19;17(20):2661-7 [9840930.001]
  • [Cites] Cell. 1998 Nov 25;95(5):605-14 [9845363.001]
  • [Cites] Oncogene. 1999 Jan 14;18(2):515-24 [9927208.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15883-91 [10336493.001]
  • [Cites] Mol Cell Biol. 1999 Sep;19(9):6195-206 [10454566.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35680-3 [11007767.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):31917-24 [10542219.001]
  • [Cites] Blood. 2000 Feb 1;95(3):745-55 [10648382.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7963-8 [10859354.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1553-77 [10887150.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):1799-806 [10925257.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6945-57 [10958690.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):625-36 [10974029.001]
  • [Cites] Eur J Immunol. 2000 Dec;30(12):3422-31 [11093160.001]
  • [Cites] Biochem J. 2001 Feb 1;353(Pt 3):417-39 [11171037.001]
  • [Cites] J Exp Med. 2001 Apr 2;193(7):873-80 [11283160.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2269-77 [11290587.001]
  • [Cites] Leuk Lymphoma. 2000 Oct;39(3-4):241-56 [11342305.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):691-7 [11477404.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):863-9 [11526403.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(21):7509-22 [11585930.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Genes Dev. 2002 Jan 15;16(2):235-44 [11799066.001]
  • [Cites] Genes Dev. 2002 Jan 15;16(2):245-56 [11799067.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):241-56 [11839776.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1352-9 [11839802.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3890-5 [11904439.001]
  • [Cites] Oncogene. 2002 Feb 28;21(10):1571-9 [11896586.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):11617-20 [11805123.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19618-26 [11919195.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 May 20;18(8):591-604 [12036489.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Stem Cells. 2002;20(5):364-79 [12351808.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):905-14 [12718877.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):1101-8 [12718894.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1115-29 [12695333.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16770-6 [12611887.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19509-17 [12621062.001]
  • [Cites] EMBO Rep. 2003 Jun;4(6):575-80 [12776177.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4717-24 [12586614.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4966-74 [12586625.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9 [12808131.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5995-6004 [12955078.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5676-84 [14500831.001]
  • [Cites] Genome Biol. 2003;4(10):R69 [14519204.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):735-46 [14527418.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1088-97 [14716294.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):127-36 [14998489.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):177-89 [14998493.001]
  • [Cites] Genes Dev. 2004 Feb 15;18(4):357-68 [15004004.001]
  • [Cites] Nat Cell Biol. 2004 Apr;6(4):308-18 [15048125.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5230-9 [15100261.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4546-56 [15121871.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):23859-62 [15100215.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30850-5 [15136563.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):1802-10 [15265911.001]
  • [Cites] Blood. 2004 Aug 15;104(4):923-32 [15155462.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7378-90 [15286700.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Methods Mol Med. 2005;105:311-22 [15492404.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5441-50 [12421919.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):910-7 [12459729.001]
  • [Cites] Nucleic Acids Res. 2002 Dec 15;30(24):5465-75 [12490715.001]
  • [Cites] EMBO Rep. 2003 Jan;4(1):59-63 [12524522.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(4):1379-89 [12556497.001]
  • [Cites] J Neurochem. 2003 Jan;84(2):397-408 [12559002.001]
  • [Cites] Oncogene. 2003 Feb 20;22(7):992-1001 [12592386.001]
  • [Cites] Nat Struct Biol. 2003 Mar;10(3):175-81 [12567184.001]
  • [Cites] Trends Immunol. 2003 Apr;24(4):197-206 [12697452.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2996-3003 [1683261.001]
  • [Cites] Mol Cell Biol. 1992 Aug;12(8):3346-55 [1630450.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2822-34 [8386317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4431-5 [8099440.001]
  • [Cites] Oncogene. 1994 Jan;9(1):1-12 [7905617.001]
  • [Cites] Mol Cell Biol. 1994 Jul;14(7):4398-407 [7516466.001]
  • [Cites] EMBO J. 1994 Sep 1;13(17):4080-6 [8076603.001]
  • [Cites] Blood. 1995 Feb 1;85(3):675-84 [7833471.001]
  • [Cites] Nature. 1995 Mar 2;374(6517):70-4 [7870176.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1113-23 [7566971.001]
  • [Cites] Gene Ther. 1994 Mar;1(2):136-8 [7584069.001]
  • [Cites] Semin Cancer Biol. 1995 Aug;6(4):195-202 [8541514.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11059-62 [8626647.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3454-64 [8668161.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):337-45 [9000579.001]
  • [Cites] Science. 1997 Jan 31;275(5300):665-8 [9005852.001]
  • [Cites] Nature. 1997 Jan 30;385(6615):454-8 [9009195.001]
  • [Cites] Curr Biol. 1997 Jun 1;7(6):375-86 [9197238.001]
  • [Cites] EMBO J. 1997 Sep 15;16(18):5662-71 [9312025.001]
  • [Cites] J Biol Chem. 1997 Nov 7;272(45):28407-14 [9353299.001]
  • [Cites] Immunity. 1997 Nov;7(5):679-89 [9390691.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1359-68 [9488451.001]
  • [Cites] Cell. 1998 Feb 20;92(4):463-73 [9491888.001]
  • [Cites] Blood. 1998 Aug 1;92(3):877-87 [9680355.001]
  • [Cites] EMBO J. 1998 Sep 15;17(18):5349-59 [9736613.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6679-97 [9774682.001]
  • (PMID = 15897879.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01HL65519; United States / NHLBI NIH HHS / HL / R01 HL066305-05; United States / NCRR NIH HHS / RR / R24RR16209; United States / NHLBI NIH HHS / HL / R01 HL065519; United States / NHLBI NIH HHS / HL / R01 HL066305; United States / NHLBI NIH HHS / HL / R01 HL066305-04; United States / NCRR NIH HHS / RR / R24 RR016209; United States / NHLBI NIH HHS / HL / HL066305-05; United States / NHLBI NIH HHS / HL / R01HL66305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins; 0 / Retinoblastoma Protein; 143275-75-6 / TLX1 protein, human; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.- / Phosphoric Monoester Hydrolases
  • [Other-IDs] NLM/ NIHMS51737; NLM/ PMC2408753
  •  go-up   go-down


42. Hsieh PP, Tseng HH, Chang ST, Fu TY, Lu CL, Chuang SS: Primary non-Hodgkin's lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan. Leuk Lymphoma; 2006 Jan;47(1):65-70
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan.
  • Primary non-Hodgkin's lymphoma of bone (PLB) is a rare disorder representing less than 1% of all non-Hodgkin's lymphomas and has rarely been reported in Taiwan.
  • The staging results were stage I (9 patients, 64%), stage II (2, 14%) and stage IV (3, 21%).
  • Eight cases (57%) were of B-cell phenotype and the remaining 6 (43%), T-cell.
  • Histologically, 7 (50%) were diffuse large B-cell lymphomas (DLBCLs) and 5 (36%) anaplastic large cell lymphomas.
  • Of the 11 patients with follow-up information, 6 (55%) died of disease within 1 year including 5 with T-cell lymphomas, while all the 5 patients surviving over 1 year were of B-cell phenotype.
  • The survival of B-cell lymphomas was significantly better than T-cell tumors (p = 0.016, log-rank test).
  • In summary, this study reported the largest series of PBL in Taiwan and confirmed that the majority was DLBCL and B-cell tumors had more favorable prognosis.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Lineage. Female. Follow-Up Studies. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Phenotype. Predictive Value of Tests. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Taiwan / epidemiology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321829.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


43. Chang ST, Hsieh YC, Lu YH, Tzeng CC, Lin CN, Chuang SS: Floral leukemic cells transformed from marginal zone lymphoma. Pathol Res Pract; 2008;204(1):23-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Floral leukemic cells transformed from marginal zone lymphoma.
  • There are three clinicopathological entities of marginal zone lymphoma (MZL), including extranodal or mucosa-associated lymphoid tissue (MALT) lymphoma and MZL of nodal (NMZL) or splenic (SMZL) type.
  • We present a stage 4 MZL involving lymph node, spleen, and bone marrow with two relapses after chemotherapy.
  • The leukemic cells at the second relapse revealed irregular nuclear contours with multilobated nuclei (so-called flower cells or floral cells) mimicking the neoplastic cells in adult T-cell leukemia/lymphoma (ATLL).
  • [MeSH-major] Bone Marrow Cells / pathology. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymph Nodes / pathology. Lymphocytes / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis. Spleen / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cell Nucleus / pathology. Cytogenetics. Diagnosis, Differential. Fatal Outcome. Gene Expression Regulation, Neoplastic. Humans. Immunoglobulin D / analysis. Male. Radiotherapy. Recurrence. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17913385.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulin D
  •  go-up   go-down


44. Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, Lim DH, Kim K, Kim SJ, Ko Y, Ki CS, Jo SJ, Lee JW, Kim WS: Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma; 2009 May;50(5):757-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma.
  • We investigated the value of Epstein-Barr virus (EBV) DNA load in unfractionated whole blood for the diagnosis and prognosis of EBV-associated lymphoma.
  • From July 2004 to July 2007, we compared EBV DNA loads in 101 patients with lymphoma and 105 control individuals.
  • The median copy number of EBV was higher in patients with EBV-positive lymphoma (p<0.001).
  • In patients with natural killer (NK)/T-cell lymphomas, the median EBV DNA load at presentation was significantly related to the stage (p = 0.011) and response (p = 0.026).
  • The newly proposed classification model for NK/T cell lymphoma showed EBV DNA load differed significantly between patients with upper and extra-upper aerodigestive tracts (p = 0.017).
  • In 16 patients with NK/T-cell lymphoma monitored serially, EBV DNA load correlated well with the treatment response and clinical course.
  • [MeSH-major] DNA, Viral / blood. Epstein-Barr Virus Infections / diagnosis. Herpesvirus 4, Human / isolation & purification. Lymphoma, Extranodal NK-T-Cell / diagnosis. Severity of Illness Index
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Gastrointestinal Tract / virology. Humans. Male. Middle Aged. Prognosis. Viral Load. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 May;50(5):684-6 [19330650.001]
  • (PMID = 19330658.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


45. Chiaretti S, Guarini A, De Propris MS, Tavolaro S, Intoppa S, Vitale A, Iacobelli S, Elia L, Ariola C, Ritz J, Foà R: ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. Blood; 2006 Jan 1;107(1):197-204
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.
  • We evaluated the expression of 2 members of the Syk family, ZAP-70 and Syk, in acute lymphoblastic leukemia (ALL) samples, using data derived from a series of 33 T-ALL and 95 B-lineage adult ALL patients analyzed by oligonucleotide arrays.
  • A high ZAP-70 expression was also found in a proportion of B-lineage ALL, the highest levels being associated with the E2A/PBX1+ group and the lowest with ALL1/AF4+ cases (P < .001).
  • In ALL, ZAP-70 expression is associated with the E2A/PBX1 rearrangement and pre-B stage and may have a prognostic role and be a candidate molecule for targeted therapies.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Adult. Cell Differentiation. Child. Enzyme Precursors / genetics. Follow-Up Studies. Gene Expression Profiling. Gene Rearrangement. Humans. Immunoglobulin mu-Chains. Intracellular Signaling Peptides and Proteins. Prognosis. Protein-Tyrosine Kinases / genetics. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160012.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Precursors; 0 / Homeodomain Proteins; 0 / Immunoglobulin mu-Chains; 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins, Fusion; 146150-85-8 / E2A-Pbx1 fusion protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


46. Niitsu N, Okamoto M, Miura I, Hirano M: Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia; 2009 Apr;23(4):777-83
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations.
  • Diffuse large B-cell lymphoma (DLBCL) having both t(14;18) and 8q24 translocations is rare.
  • A total of 1972 patients with non-Hodgkin's lymphoma were treated in the Adult Lymphoma Treatment Study Group (ALTSG) from 1998 to 2007.
  • Nineteen cases of de novo DLBCL with the dual translocation were identified.
  • The dual translocation was observed significantly more frequently among patients with high lactate dehydrogenase levels, B symptoms, bone marrow involvement and advanced stage.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 8. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic
  • [MeSH-minor] B-Lymphocytes / pathology. Bone Marrow / pathology. Disease-Free Survival. Female. Humans. L-Lactate Dehydrogenase. Lymphoma, Non-Hodgkin. Male. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151788.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


47. Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A: Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol; 2008 Jul;19(7):1312-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
  • BACKGROUND: The purpose of this study was to assess prognostic factors and outcome of patients with relapsed/refractory Hodgkin's lymphoma (HL) who received high-dose chemotherapy and autologous stem-cell transplant (ASCT).
  • Demography at ASCT was 61% stage IV, median age 31 years (18-69), median prior treatment (tx) regimens 3 (2-7), median Hasenclever index 3 (0-6); 150 patients had responding disease [54 complete remission (CR), 96 partial remission (PR)], and 45 patients had untested relapse/refractory disease.
  • Twenty (10%) patients developed second cancer (seven secondary acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS)).

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356139.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


48. Estes DA, Lovato DM, Khawaja HM, Winter SS, Larson RS: Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol; 2007 Oct;139(1):20-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples.
  • Acquired drug resistance eventually leads to treatment failure in T-cell acute lymphoblastic leukaemia (T-ALL).
  • Immunophenotypic and cytogenetic heterogeneities within T-ALL influence susceptibility to cytotoxic therapy, and little is known about the mechanisms of drug resistance at specific stages of T-cell ontogeny.
  • We developed tolerance to therapeutic concentrations of daunorubicin (DNR) and L-asparaginase (L-asp) in Jurkat (CD1a(-), sCD3(+)) and Sup T1 (CD1a(+), sCD3(-)) cell lines, having respective 'mature' and 'cortical' stages of developmental arrest.
  • Microarray analysis identified upregulation of asparagine synthetase (ASNS) and argininosuccinate synthase 1 (ASS1) to cell lines with acquired resistance to L-asp, and in the case of DNR, upregulation of ATP-binding cassette B1 (ABCB1).
  • This study expands the pool of available drug resistant cell lines having cortical and mature stages of developmental arrest, introduces three new drug resistant T-ALL cell lines, and identifies gene interactions leading to L-asp and DNR resistance.
  • [MeSH-major] Cell Line, Tumor. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Genes, MDR. Leukemia-Lymphoma, Adult T-Cell / genetics

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854304.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R01 CA114589; United States / NCI NIH HHS / CA / U10 CA98543-03-14305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / RNA, Small Interfering; 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase; EC 6.3.4.5 / Argininosuccinate Synthase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


49. Baleydier F, Decouvelaere AV, Bergeron J, Gaulard P, Canioni D, Bertrand Y, Lepretre S, Petit B, Dombret H, Beldjord K, Molina T, Asnafi V, Macintyre E: T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res; 2008 Feb 1;14(3):692-700
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome.
  • EXPERIMENTAL DESIGN: We undertook a retrospective study of 41 cytoplasmic CD3+ T-LBL (nine cases aged <16 years) by assessing stage of maturation arrest based on T cell receptor (TCR) immunogenotyping, immunohistochemistry, and quantification of the oncogenes thought to be important in immature T cell malignancies.
  • Sixteen mature TCRD(del)-LBL showed biallelic TCRD deletion and both TCRG and TCRB rearrangement, consistent with TCRalphabeta lineage restriction.
  • All Int-LBL expressed HOX11/TLX1 or HOXA9 transcripts and a proportion of the latter were associated with CALM-AF10 or NUP214-ABL fusion transcripts.
  • IM0/D-LBL were restricted to adults with extrathymic disease and bone marrow involvement, whereas Int-LBL and TCRD(del)-LBL were found in children and adults with predominantly thymic disease.
  • In adults, the Int-LBL subgroup was associated with a significantly superior clinical outcome.
  • CONCLUSION: Application of this molecular classification will allow the prospective evaluation of prognostic effects within pediatric and adult protocols.
  • [MeSH-major] Homeodomain Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Child. Child, Preschool. DNA, Neoplasm / genetics. Female. Genotype. Humans. Lymph Nodes / pathology. Male. Middle Aged. Pleural Effusion / genetics. Polymerase Chain Reaction. Receptor, Notch1 / genetics. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245528.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell; 143275-75-6 / TLX1 protein, human; 157907-48-7 / HoxA protein
  •  go-up   go-down


50. Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, Zhu Y, Zhang Y: Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control; 2008 Oct;19(8):841-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma survival patterns by WHO subtype in the United States, 1973-2003.
  • The best survival was observed for Hodgkin lymphoma among young patients, and the worst survival was observed among cases with plasma cell neoplasms, particularly plasma cell leukemia, in all racial groups.
  • Being diagnosed at a lower stage without B-symptoms and a non-HIV/AIDS status favored survival for each type of lymphoma.
  • Males typically had lower survival rates than females, but the opposite was observed for Burkitt lymphoma/leukemia among non-whites and multiple myeloma among non-Hispanic whites.
  • The differences in lymphoma survival patterns suggest that distinct prognostic risk factors impact survival by subtype and that future research and public health interventions should address racial disparities in lymphoma survivorship.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365759.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW007864; United States / FIC NIH HHS / TW / 1D43TW007864-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


51. Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Fermé C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V: High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia; 2006 May;20(5):814-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).
  • Four patients had central nervous system involvement and 12 had bone marrow involvement and 24/27 (89%) had advanced Ann Arbor stage III-IV disease.
  • Bone marrow involvement was associated with a poor outcome.
  • The Ann Arbor stage, age and serum lactate dehydrogenase level did not influence outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16511514.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Bacon CM, Diss TC, Ye H, Liu H, Goatly A, Hamoudi R, Wotherspoon A, Gascoyne RD, Dogan A, Du MQ, Isaacson PG: Follicular lymphoma of the thyroid gland. Am J Surg Pathol; 2009 Jan;33(1):22-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma of the thyroid gland.
  • The majority of lymphomas arising in the thyroid gland are mucosa-associated lymphoid tissue lymphomas and diffuse large B-cell lymphomas, which arise from a background of chronic lymphocytic thyroiditis.
  • Follicular lymphoma may also present in the thyroid gland, but its clinicopathologic features at this site are not well characterized, leading to difficulties in diagnosis and clinical management.
  • All cases showed morphology characteristic of follicular lymphoma, however, in many the interfollicular neoplastic infiltrate was particularly prominent and all lymphomas contained readily identifiable and often striking lymphoepithelial lesions, features heretofore considered indicative of mucosa-associated lymphoid tissue lymphoma at this site.
  • In 1 group, similar to typical adult follicular lymphoma, cases carried a t(14;18)/IGH-BCL2 and/or expressed Bcl-2, and were mostly CD10-positive and of World Health Organization (WHO) grade 1 to 2.
  • The 2 groups differed in clinical stage at presentation, 11 patients in the former group but none in the latter group having disease beyond the thyroid gland.
  • Appreciation of the spectrum of morphologic, immunophenotypic, and genetic characteristics of follicular lymphoma presenting in the thyroid gland should aid both diagnosis and clinical management.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Immunol. 2008 Jan;29(1):25-33 [18061541.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1254 [10561186.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):846-52 [10843287.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]
  • [Cites] Histopathology. 2000 Jul;37(1):10-8 [10931213.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):629-35 [11241227.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):105-11 [11788631.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):647-55 [11821444.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2309-17 [12399977.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):614-7 [12461620.001]
  • [Cites] Int J Surg Pathol. 2001 Oct;9(4):287-93 [12574844.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2335-9 [12406890.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2489-95 [12456507.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1012-8 [12676782.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Histopathology. 2004 Mar;44(3):268-76 [14987231.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):307-13 [15233907.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):644-53 [15286744.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1722-6 [15356642.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Histopathology. 1978 May;2(3):201-13 [580930.001]
  • [Cites] Cancer. 1979 Aug;44(2):529-42 [383257.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1979 Aug 23;383(3):293-317 [158873.001]
  • [Cites] Am J Clin Pathol. 1980 Jul;74(1):1-11 [7395811.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] N Engl J Med. 1985 Mar 7;312(10):601-4 [3838363.001]
  • [Cites] Histopathology. 1985 Jan;9(1):81-97 [3884481.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):100-4 [3708539.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] Blood. 1991 Aug 1;78(3):581-5 [1859876.001]
  • [Cites] Eur J Cancer. 1991;27(10):1201-8 [1835586.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):929-33 [1555984.001]
  • [Cites] Am J Pathol. 1992 Jul;141(1):43-52 [1632470.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6770-4 [1495966.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):1137-48 [1402658.001]
  • [Cites] Histopathology. 1994 Apr;24(4):323-7 [8045521.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Histopathology. 1996 Jan;28(1):25-32 [8838117.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4708-14 [9616169.001]
  • [Cites] Mod Pathol. 1998 Sep;11(9):864-9 [9758366.001]
  • [Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1626-35 [10193956.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):316-23 [10375088.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):263-70 [10439808.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):69-82 [15613857.001]
  • [Cites] J Pathol. 2005 Feb;205(3):329-35 [15682435.001]
  • [Cites] J Pathol. 2005 Feb;205(3):293-301 [15682443.001]
  • [Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):1-10 [15694181.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):73-8 [15735858.001]
  • [Cites] Leukemia. 2005 Apr;19(4):652-8 [15703784.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1058-63 [15815725.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6358-63 [16155020.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):529-36 [16625101.001]
  • [Cites] Histopathology. 2006 Sep;49(3):229-41 [16918969.001]
  • [Cites] Histopathology. 2006 Oct;49(4):426-9 [16978207.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):170-84 [17255761.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3076-9 [17138820.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1050-8 [17592272.001]
  • (PMID = 18830125.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274-069001; United States / NCI NIH HHS / CA / P50 CA097274-079001; United States / NCI NIH HHS / CA / CA097274-069001; United States / NCI NIH HHS / CA / CA097274-079001; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS80966; NLM/ PMC2673478
  •  go-up   go-down


53. Babusíková O, Zelezníková T, Kirschnerová G, Kankuri E: Hematogones in acute leukemia during and after therapy. Leuk Lymphoma; 2008 Oct;49(10):1935-44
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematogones in acute leukemia during and after therapy.
  • After each leukemia therapy phase, characteristics of normal regenerating B-cells may be reminiscent of and mistaken for a relapse.
  • The three individual physiological maturation phases of B-lymphocytes (hematogone stages 1, 2, and 3) were studied by four-color flow cytometry in the course of bone marrow regeneration in leukemia patients.
  • Stage 3 hematogones were found usually in children and were thus frequent in B-ALL.
  • The hematogones had an extremely high phenotypic stability unaffected by disease or therapy or by their coincidence with leukemia cells.
  • [MeSH-major] B-Lymphocytes / cytology. Bone Marrow / physiology. Leukemia / immunology. Leukemia, Myeloid, Acute / immunology. Regeneration
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Examination. Child. Child, Preschool. Flow Cytometry. Humans. Immunophenotyping. Infant. Infant, Newborn. Middle Aged. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Apr;50(4):523-4 [19373647.001]
  • (PMID = 18452085.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


54. Schützinger C, Esterbauer H, Hron G, Skrabs C, Uffmann M, Raderer M, Hauswirth A, Mannhalter C, Dieckmann K, Wagner O, Formanek M, Stift A, Friedl J, Gaiger A, Chott A, Jäger U: Prognostic value of T-cell receptor gamma rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas. Leuk Lymphoma; 2008 Feb;49(2):237-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of T-cell receptor gamma rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas.
  • Peripheral T-cell lymphomas (PTCL) have a variable outcome.
  • T-cell receptor gamma rearrangements were routinely determined in peripheral blood (n = 40) and bone marrow (n = 38) of patients with PTCL (75% unspecified) by conventional PCR at diagnosis.
  • These TCR gamma PCR positive patients had significantly more stage IV disease (14 patients of 15 patients; P = 0.001), elevated LDH (14 of 18 patients; P = 0.04), higher IPI (16 of 21 patients; P = 0.03), more anemia (15 of 19 patients; P = 0.02) and lower platelet counts (seven of seven patients; P = 0.02).
  • Patients with clinical stages I - III but molecular stage IV had an equally poor overall survival when compared with patients with clinical stage IV (15.8 vs. 13.9 months).
  • [MeSH-major] Gene Rearrangement. Lymphoma, T-Cell, Peripheral / diagnosis. Receptors, Antigen, T-Cell, gamma-delta / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Cells. Bone Marrow. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231909.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


55. Magro CM, Dyrsen ME: Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates. J Cutan Pathol; 2008 Nov;35(11):1040-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
  • BACKGROUND: Cutaneous lymphocyte-associated antigen (CLA) is expressed in resident cutaneous T lymphocytes, high endothelial venules, peripheral monocytes, granulocytes and a small percentage of memory B cells.
  • DESIGN: We investigated the expression of CLA using the HECA-452 antibody on paraffin-embedded, formalin-fixed tissue in a variety of reactive, neoplastic and preneoplastic cutaneous lymphoid infiltrates of T- and B-cell derivation.
  • High levels of CLA expression were seen in epidermotropic T-cell dyscrasias and epidermotropic T-cell lymphomas including mycosis fungoides (MF) and adult T-cell leukemia/lymphoma (ATCLL).
  • A loss of CLA in tumors normally positive for CLA was a feature of disease progression best exemplified by tumor-stage MF and acute ATCLL.
  • There was a lack of CLA expression in those lymphocytic infiltrates manifesting subcutaneous localization including lupus profundus, panniculitis-like T-cell lymphoma and atypical lymphocytic lobular panniculitis.
  • CLA expression was not only observed in primary cutaneous anaplastic large cell lymphoma but also seen in cases of nodal anaplastic large cell lymphoma secondarily involving the skin and was negative in cases of nodal anaplastic large cell lymphoma without any established skin involvement.
  • CLA was negative in the majority of B-cell lymphomas.
  • CONCLUSIONS: CLA plays a role in the pattern of T-cell lymphocyte migration in the skin and subcutis in both reactive and neoplastic states.
  • An alteration in the expression of this marker, whether it is in the context of the acquisition of expression in a cell that is normally CLA negative or its loss of expression, may define a key event in determining cutaneous and extracutaneous hematopoietic cell distribution.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Dermatitis / immunology. Lymphoma, B-Cell / immunology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell, Cutaneous / immunology. Skin Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681860.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Bani-Hani KE, Yaghan RJ, Matalka II: Primary gastric lymphoma in Jordan with special emphasis on descriptive epidemiology. Leuk Lymphoma; 2005 Sep;46(9):1337-43
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric lymphoma in Jordan with special emphasis on descriptive epidemiology.
  • The aim of this study was to examine the clinicopathological features and epidemiology of primary gastric lymphoma in Jordan as a model for Middle East countries where such data is scarce.
  • Among these there were 19 patients with primary gastric lymphoma.
  • Primary gastric lymphoma constituted 65.5% of all gastrointestinal lymphoma and 8.7% of all gastric malignancies.
  • Low-grade MALT lymphomas, high-grade MALT lymphomas, diffuse large cell B lymphomas and T cell lymphoma were found in 21.1, 26.3, 47.4 and 5.3%, respectively.
  • Primary gastric lymphoma in Jordan shares some epidemiological features with western disease.
  • Advanced stage at diagnosis correlated with poor outcome.
  • [MeSH-major] Lymphoma / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Female. Humans. Incidence. Jordan / epidemiology. Male. Middle Aged. Retrospective Studies. Sex Distribution

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109612.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D, Bensinger WI: High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma; 2008 Oct;49(10):1899-906
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
  • We analysed treatment results of two high-dose regimens: BEAM (carmustine, etoposide, cytarabine, melphalan) and BuMelTT (busulphan, melphalan, thiotepa) in autologous transplant patients with non-Hodgkin lymphoma.
  • BEAM group patients were older (mean 59.7 vs 50.1 years), more advanced (stage>or=III 88 vs 61%), had higher IPI/FLIPI scores (score>or=3, 65 vs 19%), and a higher comorbidity index (HCT-CI) (score>or=2, 40 vs 19%).
  • After adjusting for IPI/FLIPI, HCT-CI, age and stage of disease, the hazards of death, relapse and treatment failure were similar in both groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Busulfan / administration & dosage. Carmustine / administration & dosage. Cytarabine / administration & dosage. Drug Evaluation. Etoposide / administration & dosage. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Retrospective Studies. Thiotepa / administration & dosage. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949614.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  •  go-up   go-down


58. Tomic J, White D, Shi Y, Mena J, Hammond C, He L, Miller RL, Spaner DE: Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol; 2006 Mar 15;176(6):3830-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity.
  • The innate ability of B lymphoma cells to escape control by tumor-reactive T cells must be overcome to develop effective immunotherapies for these diseases.
  • Because signals from both the innate and adaptive immune systems direct the acquisition of strong immunogenicity by professional APCs, the effects of IL-2 and the TLR-7 agonist, S28690, on the immunogenic properties of chronic lymphocytic leukemia (CLL) B cells were studied.
  • The ability to stimulate T cell proliferation required additional activation of protein kinase C, which inhibited tumor cell proliferation, "switched off" IL-10 production, and caused essentially all CLL cells (regardless of clinical stage) to acquire a CD83(high)CD80(high)CD86(high)CD54(high) surface phenotype marked by the activation of STAT-1 without STAT-3.
  • These findings suggest that TLR-7 "licenses" human B cells to respond to cytokines of the adaptive immune system (such as IL-2) and provide a strategy to increase the immunogenicity of lymphoma cells for therapeutic purposes.
  • [MeSH-major] Interleukin-2 / immunology. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / metabolism. Signal Transduction. Toll-Like Receptor 7 / immunology. Toll-Like Receptor 7 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cells, Cultured. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Imidazoles / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Male. Middle Aged. Phenotype. Protein Kinase C / metabolism. Quinolines / pharmacology. Receptors, Interleukin-2 / genetics. STAT1 Transcription Factor / metabolism. STAT3 Transcription Factor / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517754.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Interleukin-2; 0 / Quinolines; 0 / Receptors, Interleukin-2; 0 / S 28690; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Toll-Like Receptor 7; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


59. Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia SJ: A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol; 2007 Feb;14(2):869-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
  • BACKGROUND: Significant antitumor T-cell responses are generated in vitro when human lymphocytes are stimulated with autologous tumor cells in the presence of bystander cells transfected with CD40L and GM-CSF.
  • Our goal was to test this bystander-based vaccine strategy in vivo in cancer patients with stage IV disease.
  • Four patients developed tumor-specific T-cell responses on ELISPOT testing.
  • One patient, who had stable disease for 24 months, demonstrated an increase in MART-1-specific T-cells by tetramer analysis after re-immunization; biopsy of the tumor that progressed 2 years after the onset of vaccination revealed a massive peritumoral and intratumoral T-cell infiltrate.
  • CONCLUSIONS: Vaccination of cancer patients with autologous tumor cells and GM.CD40L bystander cells (engineered to express GM-CSF and CD40L) is safe, can recruit and activate dendritic cells, and can elicit tumor-specific T-cell responses.
  • Phase-II trials are underway to evaluate the impact of bystander-based vaccines on melanoma and mantle cell lymphoma.
  • [MeSH-minor] Adult. Aged. Bystander Effect / immunology. Cell Line, Tumor. Dendritic Cells / immunology. Female. Humans. Immunotherapy. Leukemia, Erythroblastic, Acute. Male. Middle Aged. Neoplasm Staging. T-Lymphocytes / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Apr;15(4):1254; author reply 1255 [18165881.001]
  • (PMID = 17103257.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 147205-72-9 / CD40 Ligand; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


60. Talaulikar D, Shadbolt B, Dahlstrom JE, McDonald A: Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI). J Hematol Oncol; 2009;2:49
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).
  • BACKGROUND: The International Prognostic Index (IPI) is used to determine prognosis in diffuse large B-cell lymphoma (DLBCL).
  • One of the determinants of IPI is the stage of disease with bone marrow involvement being classified as stage IV.
  • RESULTS: Bone marrow trephines of 156 histologically proven DLBCL cases at initial diagnosis were assessed on routine histology, and immunohistochemistry using two T-cell markers (CD45RO and CD3), two B-cell markers (CD20 and CD79a) and kappa and lambda light chains.
  • Using immunophenotyping (flow cytometry and immunohistochemistry), 30 (19.2%) cases were upstaged to stage IV.
  • [MeSH-major] Diagnostic Tests, Routine. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Staging / methods. Severity of Illness Index
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ancillary Services, Hospital. Bone Marrow Examination. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Health Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3289-93 [10552937.001]
  • [Cites] Leuk Res. 2008 May;32(5):737-42 [17964648.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3889-96 [10572105.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1489-92 [10643541.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):894-9 [10679660.001]
  • [Cites] Eur J Haematol Suppl. 2001 Jul;64:46-50 [11486402.001]
  • [Cites] Haematologica. 2001 Sep;86(9):934-40 [11532621.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3073-82 [12115337.001]
  • [Cites] J Clin Pathol. 2003 Feb;56(2):129-32 [12560392.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1102-7 [15085149.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):436-41 [15314511.001]
  • [Cites] Histopathology. 2004 Sep;45(3):268-74 [15330805.001]
  • [Cites] J Clin Pathol. 1990 Aug;43(8):630-2 [2401730.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Am J Clin Pathol. 1994 Sep;102(3):284-91 [8085550.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):82-9 [7817951.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2530-9 [7595704.001]
  • [Cites] Haematologica. 1995 Jul-Aug;80(4):318-24 [7590500.001]
  • [Cites] J Clin Pathol. 1995 Nov;48(11):1035-8 [8543627.001]
  • [Cites] Leuk Lymphoma. 1995 Jun;18(1-2):145-52 [8580817.001]
  • [Cites] Med J Aust. 1996 Oct 21;165(8):424-7 [8913243.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1047-56 [9298881.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1154-9 [9506363.001]
  • [Cites] Diagn Mol Pathol. 1998 Apr;7(2):90-5 [9785007.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):179-84 [9930138.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6387-93 [16155024.001]
  • [Cites] J Mol Diagn. 2005 Nov;7(5):582-91 [16258156.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):995-1007 [16418498.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1813-7 [17064993.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):31-43 [17555445.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):119-23 [17545562.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • (PMID = 19930611.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2786909
  •  go-up   go-down


61. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN: Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma; 2010 Nov;51(11):2047-53
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma.
  • Plasmablastic lymphoma (PBL) is a distinct variant of diffuse large B-cell lymphoma initially described in HIV-positive patients.
  • In univariate analysis, age ≥60, advanced stage, bone marrow involvement, no chemotherapy, Ki-67 expression >80%, and HIV-negative status were associated with worse overall survival.
  • In multivariate analysis, advanced stage and no chemotherapy were independent adverse prognostic factors.
  • [MeSH-major] HIV Seropositivity / complications. HIV Seropositivity / pathology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. HIV-1 / immunology. Humans. Infant. Male. Middle Aged. Survival Analysis. Young Adult

  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20919850.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Mankaï A, Eveillard JR, Buhé V, Le Ster K, Loisel S, Ghedira I, Youinou P, Berthou C, Bordron A: Is the c-Cbl proto-oncogene involved in chronic lymphocytic leukemia? Ann N Y Acad Sci; 2007 Jun;1107:193-205
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is the c-Cbl proto-oncogene involved in chronic lymphocytic leukemia?
  • Chronic lymphocytic leukemia (CLL) is characterized by survival advantage and accumulation of CD5+ mature B lymphocytes.
  • Expression of zeta-chain-associated protein-70 (ZAP-70), normally present in T lymphocytes or immature B cells, is associated with disease aggressiveness, as IgVH mutational status, and some proteins implicated in survival signal pathways are found to be constitutively activated in CLL cells.
  • ZAP-70 signaling is regulated through molecular adaptors, such as the proto-oncogene product c-Casitas B lineage lymphoma (c-Cbl).
  • It appeared that expression of c-Cbl was increased in CLL and not correlated to that of B cell linker protein or ZAP-70.
  • Given that phospholipase gamma 2 (PLC gamma 2) function is also influenced by c-Cbl hypophosphorylation, the ratio of PLC gamma 2 to c-Cbl.P was measured in CLL B cells and consistently found to be >or= 1 in Binet stage B CLL patients, as opposed to stage A CLL patients.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Proto-Oncogene Proteins c-cbl / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD5 / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Phospholipase C gamma / metabolism. Phosphotyrosine / metabolism. RNA, Messenger / genetics. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804547.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / RNA, Messenger; 21820-51-9 / Phosphotyrosine; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.1.4.3 / Phospholipase C gamma; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl
  •  go-up   go-down


63. Laskar S, Muckaden MA, Bahl G, de S, Nair R, Gupta S, Bakshi A, Prabhash K, Maru D, Gujral S, Parikh P, Shrivastava SK, Dinshaw KA: Primary non-Hodgkin's lymphoma of the nasopharynx: prognostic factors and outcome of 113 Indian patients. Leuk Lymphoma; 2006 Oct;47(10):2132-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the nasopharynx: prognostic factors and outcome of 113 Indian patients.
  • This single institutional study evaluated the prognostic factors and treatment outcome of 113 Indian patients with primary nasopharyngeal non-Hodgkin's lymphoma.
  • At presentation, 28% had stage I and 62% had stage II disease.
  • Multivariate analysis showed that; age > 30 years [hazard ratio (HR) = 6.59, 95% confidence interval (CI) = 2.59 - 16.7, P < 0.0001], WHO performance score > or = 2 (HR = 2.34, 95% CI = 1.01 - 5.46, P = 0.050), T-cell lymphomas (HR = 2.81, 95% CI = 1.14 - 6.96, P < 0.001) and the presence of B symptoms (HR = 3.65, 95% CI = 1.77 - 7.53, P = 0.025), had a negative influence on survival.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Nasopharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy / methods. Female. Humans. India. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071487.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Lee J, Kim WS, Kim K, Ahn JS, Jung CW, Lim HY, Kang WK, Park K, Ko YH, Kim YH, Park C, Yoon SH, Lee WY, Chun HK: Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. Leuk Res; 2007 Mar;31(3):359-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma.
  • This study aimed to assess the efficacy of surgical treatment followed by post-surgical CHOP chemotherapy and to analyze the impact of T and N stage on survival in localized intestinal diffuse large B cell lymphoma (DLBL) patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / surgery. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prednisolone / therapeutic use. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2007 Mar;31(3):287-9 [17010434.001]
  • (PMID = 16930692.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


65. Kyllönen H, Pasanen AK, Kuittinen O, Haapasaari KM, Turpeenniemi-Hujanen T: Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody. Leuk Lymphoma; 2009 Aug;50(8):1301-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
  • Diffuse large B-cell lymphomas (DLBCLs) are a heterogeneous group of lymphomas, with no accepted biological prognostic markers in routine clinical practice.
  • In this study, in patients treated with modern lymphoma treatments (5-year cause-specific survival 69.8%) MMP-2, MMP-9, TIMP-1 or TIMP-2 expression or GC phenotype did not correlate with survival.
  • International Prognostic Index (IPI) and stage were the only factors, which retained their prognostic significance in this patient material.
  • Prognostic markers are dependent on the lymphoma treatments used.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinal Center / pathology. Lymphoma, Large B-Cell, Diffuse / mortality. Matrix Metalloproteinase 9 / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Matrix Metalloproteinase 2 / analysis. Middle Aged. Neoplasm Staging. Prednisolone / administration & dosage. Prednisone / administration & dosage. Prognosis. Rituximab. Survival Rate. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-2 / analysis. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19811332.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Neoplasm Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; VB0R961HZT / Prednisone; CHOEP protocol; CHOP protocol
  •  go-up   go-down


66. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, Dastugue N, Brousset P: A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood; 2007 Apr 15;109(8):3417-23
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
  • We report a novel t(7;9)(q11;p13) translocation in 2 patients with B-cell acute lymphoblastic leukemia (B-ALL).
  • After cloning the full-length cDNA of the chimeric gene, confocal microscopy of transfected NIH3T3 cells and Burkitt lymphoma cells (DG75) demonstrated that PAX5-ELN was localized in the nucleus.
  • Since PAX5 is essential for B-cell differentiation, this translocation may account for the blockage of leukemic cells at the pre-B-cell stage.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. Elastin / genetics. Genes, Dominant. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Animals. Antigens, CD19 / biosynthesis. Antigens, CD19 / genetics. Cell Differentiation / genetics. Cell Nucleus / genetics. Cell Nucleus / metabolism. Cell Nucleus / pathology. HeLa Cells. Humans. Male. Mice. NIH 3T3 Cells. Promoter Regions, Genetic / genetics. Transcription, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179230.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / B-Cell-Specific Activator Protein; 0 / Oncogene Proteins, Fusion; 0 / PAX5 protein, human; 9007-58-3 / Elastin
  •  go-up   go-down


67. Wu H, Ma Y, Zhu Y, Shen Y, Gu C, Ye Z, Lin H: Expression of BIRC7 protein and mRNA in non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Jun;47(6):1110-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of BIRC7 protein and mRNA in non-Hodgkin's lymphoma.
  • We investigated the expression of BIRC7, survivin, Bcl-2, Bax, p53 and p170 proteins in 167 cases of non-Hodgkin's lymphoma (NHL) and 10 cases of non-specific lymphadenitis by tissue microarray-based immunohistochemistry.
  • BIRC7 mRNA in three cell lines and 16 cases of NHL were detected by reverse transcriptase-polymerase chain reaction.
  • BIRC7 expression did not correlate with clinic pathologic factors such as sex, age, stage and grade, but overexpression of BIRC7 was positively correlated with aggression of NHL cells (P < 0.05).
  • [MeSH-major] Adaptor Proteins, Signal Transducing / biosynthesis. Apoptosis. Gene Expression Regulation, Neoplastic. Inhibitor of Apoptosis Proteins / biosynthesis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / biosynthesis. RNA, Neoplasm / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Female. Humans. Jurkat Cells. K562 Cells. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840203.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BIRC7 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Neoplasm
  •  go-up   go-down


68. Guo Z, Dose M, Kovalovsky D, Chang R, O'Neil J, Look AT, von Boehmer H, Khazaie K, Gounari F: Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood; 2007 Jun 15;109(12):5463-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation.
  • We show here that activated beta-catenin stalls the developmental transition from the double-positive (DP) to the single-positive (SP) thymocyte stage and predisposes DP thymocytes to transformation. beta-Catenin-induced thymic lymphomas have a leukemic arrest at the early DP stage.
  • Lymphomagenesis requires Rag activity, which peaks at this developmental stage, as well as additional secondary genetic events.
  • Thus, beta-catenin activation may provide a mechanism for the induction of T-cell-acute lymphoblastic leukemia (T-ALL) that does not depend on Notch activation.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1996 Sep 2;15(17):4526-36 [8887544.001]
  • [Cites] Science. 1998 Apr 24;280(5363):596-9 [9554852.001]
  • [Cites] EMBO J. 1997 Feb 3;16(3):441-50 [9034327.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2228-38 [10688669.001]
  • [Cites] Curr Opin Immunol. 2000 Apr;12(2):166-72 [10712939.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] Immunity. 1998 Jan;8(1):11-20 [9462507.001]
  • [Cites] Cell Growth Differ. 1998 Feb;9(2):131-8 [9486849.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):10823-6 [9556553.001]
  • [Cites] J Immunol. 1998 Oct 15;161(8):3984-91 [9780167.001]
  • [Cites] EMBO J. 1999 May 17;18(10):2823-35 [10329628.001]
  • [Cites] Mol Cell Biol. 1999 Jun;19(6):4414-22 [10330181.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Nat Immunol. 2005 Aug;6(8):800-9 [16025118.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3131-7 [16384926.001]
  • [Cites] Blood. 2006 May 15;107(10):4115-21 [16449526.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Eur J Immunol. 2006 Sep;36(9):2376-83 [16897815.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1037-47 [16951686.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1048-56 [16951689.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1967-77 [16990763.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Blood. 2012 Oct 25;120(17):3625 [22898606.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3337-48 [10880446.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Immunity. 2001 Jan;14(1):45-55 [11163229.001]
  • [Cites] Eur J Immunol. 2001 Jan;31(1):285-93 [11265645.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):235-41 [11224523.001]
  • [Cites] Immunity. 2001 Mar;14(3):253-64 [11290335.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):691-7 [11477404.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):863-9 [11526403.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S13-9 [11983149.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3414-21 [12032779.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Curr Opin Immunol. 2003 Apr;15(2):204-8 [12633671.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Nat Immunol. 2003 Dec;4(12):1177-82 [14608382.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):91-102 [14749129.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23 [14973184.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):336-42 [15095297.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):329-40 [15288258.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7 [15314234.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Nature. 1989 Nov 9;342(6246):185-9 [2572968.001]
  • [Cites] Cell. 1991 May 31;65(5):737-52 [1904008.001]
  • [Cites] Nature. 1994 Jan 6;367(6458):80-3 [7906389.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):25-34 [8006585.001]
  • [Cites] Nature. 1995 Jun 29;375(6534):795-8 [7596413.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] J Immunol. 1996 Aug 1;157(3):978-83 [8757600.001]
  • [Cites] EMBO J. 1998 Mar 2;17(5):1371-84 [9482734.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2205-12 [8950988.001]
  • (PMID = 17317856.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK34928; United States / NCI NIH HHS / CA / R01 CA104547; United States / NIDDK NIH HHS / DK / P30 DK034928; United States / NCI NIH HHS / CA / R01 CA104547-01A1; United States / NIAID NIH HHS / AI / R01 AI059676-01; United States / NIAID NIH HHS / AI / R01 AI059676
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Myc protein, mouse; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptors, Notch; 0 / beta Catenin; 128559-51-3 / RAG-1 protein
  • [Other-IDs] NLM/ PMC1890819
  •  go-up   go-down


69. Lowe T, Luu T, Shen J, Bhatia S, Shibata S, Stein A, Somlo G: Male breast cancer 15 years after allogeneic hematopoietic cell transplantation including total body irradiation for recurrent acute lymphoblastic leukemia. Onkologie; 2008 May;31(5):266-9
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer 15 years after allogeneic hematopoietic cell transplantation including total body irradiation for recurrent acute lymphoblastic leukemia.
  • CASE REPORTS: We report here the case of a 34-year-old man who developed stage IIB node-positive breast cancer almost 15 years following total body irradiation and allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia.
  • [MeSH-major] Breast Neoplasms, Male / etiology. Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasms, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Whole-Body Irradiation / adverse effects
  • [MeSH-minor] Adult. Humans. Longitudinal Studies. Male. Neoplasm Recurrence, Local


70. Saxena A, Rai A, Raina V, Seth T, Mitra DK: Expression of CD13/aminopeptidase N in precursor B-cell leukemia: role in growth regulation of B cells. Cancer Immunol Immunother; 2010 Jan;59(1):125-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD13/aminopeptidase N in precursor B-cell leukemia: role in growth regulation of B cells.
  • Expression of cell surface CD13 in acute B-cell leukemia (ALL-B) is often viewed, as an aberrant expression of a myeloid lineage marker.
  • Here, we attempted to study the stage specific expression of CD13 on ALL-B blasts and understand its role in leukemogenesis as pertaining to stage of B-cell ontogeny.
  • Among 68 cases of early B-cell ALL, 22 cases with distinct immunophenotype was identified as immature B-cell ALL.
  • This strongly indicates leukemogenesis at an early stage of B-cell development.
  • By blocking their cell surface CD13 in leukemic blasts with monoclonal antibody we were able to inhibit their proliferation.
  • We hypothesized that neoplastic transformation at this stage may be facilitated by CD13.
  • CD13 may thus be an important target for novel molecular therapy of early stage acute B-cell leukemia.
  • [MeSH-major] Antigens, CD13 / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cells, B-Lymphoid / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562339.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


71. Qin Y, Shi YK, He XH, Han XH, Zhou SY, Liu P, Yang JL, Yang S, Zhang CG, Dong M, Zhou LQ, Wang JW, Feng FY, Sun Y: [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients]. Zhonghua Zhong Liu Za Zhi; 2009 Jun;31(6):469-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
  • OBJECTIVE: To retrospectively analyze and compare the treatment efficiency of CHOP-based regimens with or without high-dose consolidation treatment combined with hematopoietic stem cell transplantation (HDT-HSCT) in the patients with lymphoblastic lymphoma (LBL).
  • RESULTS: Of the 63 patients, 57 had a T-LBL and 6 B-LBL, with a median age of 20 years, 19 (30.2%) had a stage I-II diseases and 44 (69.8%) stage III-IV diseases, 61.9% presented with a mediastinal mass.
  • Bone marrow involvement, age > or =20 years, short response duration and primary refractory disease were factors significantly associated with poor outcome.
  • CONCLUSION: Short term treatment with a CHOP-based regimen is not sufficient for the patients with lymphoblastic lymphoma.
  • High-dose consolidation treatment and hematopoietic stem cell transplantation may improve overall survival and disease free survival.
  • Bone marrow involvement, age >20 years, and short response duration and primary refractory disease are all the factors significantly associated with poor outcome.
  • For the patients with bone marrow involvement, allohematopoietic stem cell transplantation is superior to auto-hematopoietic stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950562.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


72. Wood L, Robinson R, Gavine L, Juritz J, Jacobs P: A single unit lymphoma experience: outcome in a Cape Town academic centre. Transfus Apher Sci; 2007 Aug;37(1):93-102
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single unit lymphoma experience: outcome in a Cape Town academic centre.
  • Fifty-seven percent were stage I or II and 21% had nodal disease above and below the diaphragm whilst in the remainder cells were present in the circulation and this included the subset of chronic lymphocytic leukaemia -- small lymphocytic lymphoma.
  • Analysed by disease category Hodgkin lymphoma (n=17) when managed according to the German Study Group protocols and hairy cell leukaemia (n=10) treated with two chlorodeoxyadenosine -- both had a stable plateau in excess of 90%.
  • Curves for the aggressive or diffuse large B-cell lymphoma (n=44) fell initially to 48%, but relapse continued in stages III and IV to the current level of 18% when receiving cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone on the 21-day schedule.
  • Chronic lymphocytic leukaemia -- small lymphocytic lymphoma (n=58) were initially given pulsed chlorambucil and sustained response was over 90% with low bulk, but declined to reach 30% as prognostic score rose.
  • [MeSH-major] Hospitals, Private. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma / mortality. Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Cohort Studies. Developing Countries. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Risk Factors. South Africa. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931976.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


73. Garderet L, Mazurier C, Pellat-Deceunynck C, Karim A, Baudin B, Funck-Brentano C, Bouchet S, Geffroy A, Bataille R, Gorin NC, Lopez M: Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma. Leuk Lymphoma; 2006 Jul;47(7):1340-7
Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma.
  • This study evaluated the feasibility of using dendritic cells (DCs) to generate, ex vivo, anti-tumor cytotoxic T lymphocytes (CTL) in patients with stage III multiple myeloma (MM).
  • Nucleated cells from eight patients who had received chemotherapy (three of whom had undergone autologous hemopoeitic stem cell transplantation) were collected by apheresis.
  • The DCs were pulsed either with the idiotypic paraprotein (regarded as a tumor-specific antigen) or with autologous MM cell lysate before co-culture.
  • Specific T-cell responses were measured in IFNgamma enzyme-linked immunospot and chromium release assays of autologous plasmocyte targets.
  • A slight increase in IFNgamma secretion by T-cells was observed for two patients (DCs pulsed with idiotypic paraprotein for one, MM cell lysate for the other).
  • In conclusion, the T-cell response to pulsed DCs was very weak or absent.
  • [MeSH-major] Cell Transplantation / methods. Dendritic Cells / cytology. Immunoglobulin Idiotypes. Multiple Myeloma / therapy. T-Lymphocytes / metabolism
  • [MeSH-minor] Adult. Aged. Blood Component Removal. CD8-Positive T-Lymphocytes / metabolism. Cell Differentiation. Chromium / metabolism. Coculture Techniques. Female. Humans. Male. Middle Aged. Monocytes / metabolism. Tumor Necrosis Factor-alpha / biosynthesis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923566.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Idiotypes; 0 / Tumor Necrosis Factor-alpha; 0R0008Q3JB / Chromium
  •  go-up   go-down


74. Barzilai A, Trau H, David M, Feinmesser M, Bergman R, Shpiro D, Schiby G, Rosenblatt K, Or R, Hodak E: Mycosis fungoides associated with B-cell malignancies. Br J Dermatol; 2006 Aug;155(2):379-86
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycosis fungoides associated with B-cell malignancies.
  • BACKGROUND: The coexistence of mycosis fungoides, a peripheral T-cell lymphoma, and B-cell malignancies or Hodgkin's lymphoma in the same patient is unusual.
  • OBJECTIVES: To detect cases of mycosis fungoides associated with B-cell malignancies or Hodgkin's lymphoma and to analyse the characteristics of and the interplay between the lymphoproliferative neoplasms.
  • METHODS: Patients with mycosis fungoides who had B-cell malignancies or Hodgkin's lymphoma were selected from among 398 patients either treated or followed up in two tertiary medical centres during a 7-year period.
  • RESULTS: Eleven patients with mycosis fungoides and B-cell malignancy were detected (seven of non-Hodgkin's lymphoma, three of chronic lymphocytic leukaemia, one of multiple myeloma).
  • No case of Hodgkin's lymphoma was found.
  • In seven patients the mycosis fungoides preceded the B-cell malignancy whereas in four it was the B-cell malignancy which occurred first.
  • Among the four patients in whom the appearance of mycosis fungoides followed the B-cell malignancy, three had been treated with multiagent chemotherapy.
  • Two patients who presented with early-stage mycosis fungoides (IA) as the first lymphoma developed mycosis fungoides tumours after becoming immunosuppressed.
  • In two patients infiltrates composed of both malignant T- and B-cell populations were found in a single biopsy.
  • One showed two distinct populations of the malignant cells in the skin tumour, thus constituting a classical composite lymphoma of mycosis fungoides and chronic lymphocytic leukaemia, while in the other patient the two malignant populations of marginal B-cell lymphoma and mycosis fungoides (as evidenced by both phenotypic and genotypic findings) were intermingled.
  • CONCLUSIONS: This case series indicates that while the coexistence of Hodgkin's lymphoma and mycosis fungoides is extremely rare, the association of mycosis fungoides and B-cell malignancies is not as rare as reflected in the literature, with non-Hodgkin's lymphoma constituting the most common associated B-cell malignancy.
  • In this series as well as in the cases reported in the literature mycosis fungoides usually preceded the development of B-cell malignancies, which may be in accordance with previous reports of an increased risk of developing a second haematological neoplasm.
  • It is suggested that for greater precision the criteria for diagnosis of composite lymphoma of the skin should include both phenotypic and genotypic features.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Mycosis Fungoides / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882178.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


75. Poirel HA, Cairo MS, Heerema NA, Swansbury J, Aupérin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphaël M, McCarthy K, Sposto R, Gerrard M, Bernheim A, Patte C, FAB/LMB 96 International Study Committee: Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia; 2009 Feb;23(2):323-31
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
  • Clinical studies showed that advanced stage, high LDH, poor response to reduction therapy and combined bone marrow and central nervous system disease are significantly associated with a decreased event-free survival (EFS) in pediatric mature B-cell non-Hodgkin's lymphoma (B-NHL) treated on FAB/LMB96.
  • Although rearranged MYC/8q24 (R8q24) is characteristic of Burkitt lymphoma (BL), little information is available on other cytogenetic abnormalities and their prognostic importance.
  • We performed an international review of 238 abnormal karyotypes in childhood mature B-NHL treated on FAB/LMB96: 76% BL, 8% Burkitt-like lymphoma, 13% diffuse large B-cell lymphoma (DLBCL).
  • The main BL R8q24-associated chromosomal aberrations were +1q (29%), +7q and del(13q) (14% each).
  • Incidence of R8q24 (34%) was higher than reported in adult DLBCL.
  • The prognostic value of cytogenetic abnormalities on EFS was studied by Cox model controlling for the known risk factors: R8q24, +7q and del(13q) were independently associated with a significant inferior EFS (hazard ratio: 6.1 (P=0.030), 2.5 (P=0.015) and 4.0 (P=0.0003), respectively).
  • The adverse prognosis of R8q24 was observed only in DLBCL, whereas del(13q) and +7q had a similar effect in DLBCL and BL.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Semin Cancer Biol. 2002 Oct;12(5):381-7 [12191637.001]
  • [Cites] Leukemia. 2003 Oct;17(10):2016-24 [14513052.001]
  • [Cites] Leukemia. 2004 Mar;18(3):584-8 [14712292.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Mar;26(3):169-78 [15125609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Ann Genet. 1989;32(1):26-32 [2751244.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Nov;1(2):115-8 [2487150.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jun;60(2):206-9 [1606568.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3905-14 [7579360.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):1-19 [9720711.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):3015-23 [15728515.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):616-22 [16127683.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):840-7 [18371107.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):510-18 [10653866.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):47-51 [10690386.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1099-106 [11697627.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):115-21 [15350300.001]
  • [Cites] Int J Cancer. 1976 Jan 15;17(1):47-56 [946170.001]
  • [Cites] Cancer Genet Cytogenet. 1981 Jun;3(4):307-15 [7260888.001]
  • [Cites] Nature. 1982 Jul 29;298(5873):474-6 [6806672.001]
  • [Cites] Cell. 1983 Oct;34(3):779-87 [6414718.001]
  • [Cites] C R Acad Sci III. 1984;298(6):143-5 [6324967.001]
  • [Cites] IARC Sci Publ. 1985;(60):65-80 [2998996.001]
  • (PMID = 19020548.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-06; United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS107551; NLM/ PMC2988438
  • [Investigator] Avet-Loiseau H; Baranger L; Barin C; Bastard C; Bernheim A; Berthéas MF; Bilhou-Nabera C; Borie C; Caillet-Bauchu E; Capdano AM; Collonge-Rame MA; Cornillet P; Couturier J; Dastugue N; Daudignon A; Gachard N; Grégoire MJ; Heimann P; Henry C; Laï JL; Leroux D; Lessard M; Luquet I; Mellink CH; Nadal N; Pagès MP; Penther D; Perissel B; Raynaud S; Talman P; Taviaux S; Tigaud I; Van den Akker J; Beigel J; Benn P; Cantu E; Carlson K; Cooley L; Dawson A; Dev VG; Dewald G; Drumheller T; Fink J; Gadi I; Hanna J; Glassman A; Harrison K; Heerema N; Higgins J; Higgins R; Hirsch B; Horsman D; Kalousek D; Koduru P; Lebo R; Li X; Magenis RE; McFadden K; McGavron L; McMorrow L; Murch A; Opheim K; Panzar D; Pasztor L; Pettigrew A; Philips C; Rao K; Rao PN; Rouston D; Sanger W; Satya-Prakash KL; Schwartz S; Sekhon GS; Shaw G; Shekter-Levin S; Spinner N; Stanley W; Storto P; Thangavelu M; Theil K; Vance G; VanDyke D; Zadeh T; Andrews K; Booth M; Bown N; Davies T; Grace E; Griffiths M; Howard P; Hughes D; Kempski H; Lillington D; Lowther G; Martin K; Roberts P; Ross F; Sadler J; Stallings R; Stevenson D; Swansbury J; Talley P; Telford N; Walker H
  •  go-up   go-down


76. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S: Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia; 2006 Sep;20(9):1533-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation.
  • We report the results of two prospective phase II studies investigating the role of high-dose sequential chemotherapy, followed by autologous stem cell transplantation (ASCT) in 62 patients with advanced stage peripheral T-cell lymphomas (PTCLs) at diagnosis.
  • Conditioning regimen consisted of mitoxantrone (60 mg/m2) and melphalan (180 mg/m2) or carmustine, etoposide, Ara-C and melphalan followed by peripheral blood stem cell autografting.
  • OS and EFS were significantly better in patients with anaplastic lymphoma-kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL), as compared with the remaining PTCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / surgery. Stem Cell Transplantation
  • [MeSH-minor] Adult. Combined Modality Therapy. Follow-Up Studies. Humans. Middle Aged. Prognosis. Prospective Studies. Transplantation Conditioning. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871285.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


77. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A: Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol; 2007 Sep 1;25(25):3915-22
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
  • PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of CNS involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's lymphoma (NHL), with special attention to differences according to NHL subtype.
  • RESULTS: CNS involvement was diagnosed in 141 (5.9%) of 2,381 patients and was associated with an advanced stage of NHL.
  • The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
  • Although CNS disease had no impact on pEFS for advanced-stage T-LBL patients, CNS-positive patients with BL/B-ALL had a worse average outcome than CNS-negative patients with stage IV BL/B-ALL (60% +/- 5% v 81% +/- 3%; P < .001).
  • In multivariate analysis, CNS disease was the strongest predictor for relapse in BL/B-ALL patients with advanced-stage disease.
  • [MeSH-major] Brain Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Epidural Neoplasms / epidemiology. Epidural Neoplasms / therapy. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prevalence. Prognosis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Stefanovic A, Morgensztern D, Fong T, Lossos IS: Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database. Leuk Lymphoma; 2008 Jul;49(7):1311-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database.
  • Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT).
  • There is limited information on clinical presentation, natural history and treatment of this type of lymphoma.
  • We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our institution and patients from the surveillance epidemiology and end results (SEER) database.
  • Twenty-one patients (median age 57) with disease stage IE (n = 10) and IV (n = 11), were treated at our institution.
  • We identified 326 patients (59% females and 41% males; median age 68 [30 to 85) with BALT lymphoma in the SEER database.
  • Fifty-five per cent had stage IE, 10% stage IIE, 3% stage IIIE, and 22% stage IV disease.
  • [MeSH-major] Lung Neoplasms. Lymphoma, B-Cell, Marginal Zone
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Databases, Factual. Disease Progression. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604720.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


79. Paul JT, Henson ES, Mai S, Mushinski FJ, Cheang M, Gibson SB, Johnston JB: Cyclin D expression in chronic lymphocytic leukemia. Leuk Lymphoma; 2005 Sep;46(9):1275-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D expression in chronic lymphocytic leukemia.
  • Although the majority of circulating leukemic cells in chronic lymphocytic leukemia (CLL) are in G0/early G1, recent studies have shown that these cells have undergone multiple cell divisions.
  • In this study, we have determined whether there are abnormalities in cell cycle control in CLL by examining the three cyclin D isoforms in 43 patients and correlating the findings with clinical features.
  • Expression of the cyclin D isoforms was two- to four-fold greater in normal T cells than B cells, and the order of expression for both cell types was D2 > D3 > D1.
  • Both cyclin D1 and D3 mRNA levels correlated positively with lymphocyte doubling time (LDT) and inversely with Rai stage and duration of disease.
  • Thus, cyclin D1 and D3 are relatively overexpressed in CLL cells and patients with higher levels have low stage disease, long LDT and prolonged survival.
  • [MeSH-major] Cyclins / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Cyclin D. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Protein Isoforms / analysis. RNA, Messenger. Survival Rate


80. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM: Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma; 2005 Dec;46(12):1721-7
Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
  • Non-Hodgkin's lymphoma of the paranasal sinus is an uncommon presentation of extranodal lymphoma.
  • In British Columbia (population 4 million), a central database for lymphomas has allowed us to accurately track cases of paranasal sinus lymphoma diagnosed since 1980.
  • A retrospective review was performed on the 44 patients who presented with primary paranasal sinus lymphoma (stage I or II) between 1980 and 1999.
  • Complete diagnostic and follow-up data including stage, treatment, response rates, sites of relapse and survival data were available for all patients.
  • The types of lymphoma found were: diffuse large B cell (including immunoblastic), n = 37 (84%); T/NK nasal type, n = 3 (8%); peripheral T cell, not otherwise classified, n = 2 (4%); and others, n = 2 (4%).
  • Introduction of intrathecal chemoprophylaxis was also associated with an improvement in overall survival from 20% to 51% and disease-specific survival from 40% to 65%.
  • Primary paranasal sinus lymphoma is an uncommon presentation of lymphoma that carries the potential risk of spreading to the leptomeninges.
  • [MeSH-major] Chemoprevention. Lymphoma, Non-Hodgkin / physiopathology. Paranasal Sinus Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Survivors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263574.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR: The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood; 2010 Nov 25;116(22):4532-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
  • Monoclonal antibodies and T cells modified to express chimeric antigen receptors specific for B-cell lineage surface molecules such as CD20 exert antitumor activity in B-cell malignancies, but deplete normal B cells.
  • The receptor tyrosine kinase-like orphan receptor 1 (ROR1) was identified as a highly expressed gene in B-cell chronic lymphocytic leukemia (B-CLL), but not normal B cells, suggesting it may serve as a tumor-specific target for therapy.
  • We analyzed ROR1-expression in normal nonhematopoietic and hematopoietic cells including B-cell precursors, and in hematopoietic malignancies.
  • ROR1 has characteristics of an oncofetal gene and is expressed in undifferentiated embryonic stem cells, B-CLL and mantle cell lymphoma, but not in major adult tissues apart from low levels in adipose tissue and at an early stage of B-cell development.
  • We constructed a ROR1-specific chimeric antigen receptor that when expressed in T cells from healthy donors or CLL patients conferred specific recognition of primary B-CLL and mantle cell lymphoma, including rare drug effluxing chemotherapy resistant tumor cells that have been implicated in maintaining the malignancy, but not mature normal B cells.
  • T-cell therapies targeting ROR1 may be effective in B-CLL and other ROR1-positive tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2008 Jan;118(1):294-305 [18060041.001]
  • [Cites] Hum Gene Ther. 2007 Aug;18(8):712-25 [17685852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3047-52 [18287027.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):396-404 [18223214.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] Int J Cancer. 2008 Sep 1;123(5):1190-5 [18546292.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2427-37 [18551193.001]
  • [Cites] Leuk Lymphoma. 2008 Jul;49(7):1360-7 [18604725.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2261-71 [18509084.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4912-20 [18794548.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):605-11 [19075267.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4759-68 [19567591.001]
  • [Cites] Leukemia. 2010 Mar;24(3):563-72 [20072155.001]
  • [Cites] Semin Hematol. 2010 Apr;47(2):187-98 [20350666.001]
  • [Cites] Blood. 2010 Apr 1;115(13):2619-29 [19965642.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56 [20304086.001]
  • [Cites] Expert Rev Hematol. 2009 Oct;2(5):517-32 [21083018.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):70-5 [11753365.001]
  • [Cites] Cell Mol Life Sci. 2002 Jan;59(1):83-96 [11846036.001]
  • [Cites] J Anat. 2002 Mar;200(Pt 3):249-58 [12033729.001]
  • [Cites] Mol Ther. 2004 Apr;9(4):577-86 [15093188.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):469-79 [15314075.001]
  • [Cites] Cell. 1974 Oct;3(2):127-33 [4426090.001]
  • [Cites] J Cell Biol. 1985 Mar;100(3):965-73 [3972906.001]
  • [Cites] J Immunol Methods. 1990 Apr 17;128(2):189-201 [1691237.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):26181-90 [1334494.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Immunol Cell Biol. 1997 Oct;75(5):446-55 [9429891.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3535-42 [15304387.001]
  • [Cites] Methods Cell Biol. 2004;75:559-76 [15603442.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):591-600 [15864305.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1797-805 [15965501.001]
  • [Cites] Stem Cells. 2006 Dec;24(12):2677-84 [16916927.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):385-97 [17707828.001]
  • [CommentIn] Blood. 2010 Nov 25;116(22):4387-8 [21109622.001]
  • (PMID = 20702778.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / R01 CA136551; United States / NCI NIH HHS / CA / CA136551; United States / NCI NIH HHS / CA / CA18029
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; EC 2.7.10.1 / ROR1 protein, human; EC 2.7.10.1 / Receptor Tyrosine Kinase-like Orphan Receptors
  • [Other-IDs] NLM/ PMC2996114
  •  go-up   go-down


82. Gora-Tybor J, Jamroziak K, Szmigielska-Kaplon A, Krawczynska A, Lech-Maranda E, Wierzbowska A, Jesionek-Kupnicka D, Blonski JZ, Robak T: Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma; 2009 Jan;50(1):62-7
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia.
  • An increased angiogenesis has been documented in bone marrow and lymph nodes of patients with chronic lymphocytic leukemia (CLL).
  • Furthermore, the rCECs number was higher in advanced versus low clinical stage CLL (median 17.5 cells/microL vs. 13.5 cells/microL, p = 0.05).
  • In conclusion, the number of CECs is increased in CLL and correlates with stage of the disease, but does not seem to directly reflect the intensity of neovascularisaton in the bone marrow.
  • [MeSH-major] Cell Movement. Endothelial Cells / cytology. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers. Bone Marrow / blood supply. Female. Health. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Jan;50(1):8-9 [19172495.001]
  • (PMID = 19125384.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


83. Hara S, Yokote T, Oka S, Akioka T, Kobayashi K, Hirata Y, Miyoshi T, Tsuji M, Hanafusa T: Endophthalmitis due to Trichosporon beigelii in acute leukemia. Int J Hematol; 2007 Jun;85(5):415-7
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endophthalmitis due to Trichosporon beigelii in acute leukemia.
  • The administration of AMPH-B is likely to be more effective in treating endophthalmitis due to trichosporonosis when the disease is at an early stage.
  • [MeSH-major] Endophthalmitis / complications. Endophthalmitis / microbiology. Leukemia, Myeloid / complications. Mycoses / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Trichosporon
  • [MeSH-minor] Acute Disease. Adult. Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Drug Resistance, Fungal. Female. Fluconazole / administration & dosage. Flucytosine / administration & dosage. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562617.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole; D83282DT06 / Flucytosine
  •  go-up   go-down


84. Tomomatsu J, Isobe Y, Oshimi K, Tabe Y, Ishii K, Noguchi M, Hirano T, Komatsu N, Sugimoto K: Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior. Leuk Lymphoma; 2010 Dec;51(12):2230-9
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior.
  • Chronic lymphocytic leukemia (CLL) is relatively rare in Japan.
  • Among 46 cases of mature B-cell leukemia, we identified 28 Japanese patients with CLL, including prolymphocytoid and lymphoplasmacytoid morphological variants.
  • Binet A stage (p = 0.003), low-risk category according to the modified Rai classification (p = 0.016), and ≤ 15 U/mL level of serum thymidine kinase activity (p = 0.016) were associated with prolongation of treatment-free status.
  • [MeSH-major] Immunophenotyping. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Disease Progression. Female. Gene Frequency. Genes, Immunoglobulin Heavy Chain / genetics. Genes, bcl-2 / genetics. Humans. Immunoglobulin Variable Region / genetics. Male. Middle Aged. Mutation. Population. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067444.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / IGH-CCND1 fusion protein, human; 0 / Immunoglobulin Variable Region; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


85. Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T: Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma; 2006 Oct;47(10):2140-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG).
  • The aim of this retrospective study was to illustrate the clinicopathologic data and the treatment results in patients with primary gastrointestinal tract non-Hodgkin's lymphoma (GI NHL).
  • Extranodal marginal zone B-cell lymphoma (MZBL) (i.e., low-grade lymphoma of mucosa-associated lymphoid tissue type) accounted for 48.4% of lymphomas.
  • Aggressive lymphomas (diffuse large B-cell lymphoma [DLBL]) accounted for 44.5%.
  • The major prognostic factor for outcome in the present study was the stage of the disease.
  • Patients with localized lymphoma (stage I and II) had significantly longer DFS and OS (DFS and OS at 3-year: 83% and 87%, respectively) than patients with extended disease (stage III and IV) (DFS and OS at 3-year: 46% and 60%, respectively) (P < 0.0001).
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Greece. Humans. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071488.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol; 2010 Apr 1;28(10):1756-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
  • PURPOSE: Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination with chemotherapy.
  • Promising results have previously been reported in nonrandomized studies in patients with chronic lymphocytic leukemia (CLL).
  • A total of 552 patients with Binet stage A (1%), B (59%), or C (31%) disease entered the study and were randomly assigned to receive R-FC (n = 276) or FC (n = 276).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Female. Humans. Male. Middle Aged. Quality of Life. Retreatment. Rituximab

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20194844.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


87. Li X, Gounari F, Protopopov A, Khazaie K, von Boehmer H: Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. J Exp Med; 2008 Nov 24;205(12):2851-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations resulting in overexpression of intracellular Notch1 (ICN1) are frequently observed in human T cell acute lymphoblastic leukemia (T-ALL).
  • Early consequences are the generation of polyclonal nontumorigenic CD4(+)8(+) T cell receptor (TCR)-alphabeta(+) cells that do not qualify as tumor precursors despite the observation that they overexpress Notch 1 and c-Myc and degrade the tumor suppressor E2A by posttranslational modification.
  • The first tumorigenic cells are detected among more immature CD4(-)8(+)TCR-alphabeta(-) cells that give rise to monoclonal tumors with a single, unique TCR-beta chain and diverse TCR-alpha chains, pinpointing malignant transformation to a stage after pre-TCR signaling and before completion of TCR-alpha rearrangement.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Nature. 1985 Mar 7-13;314(6006):103-7 [2983227.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Cell. 2007 Jun 1;129(5):879-90 [17540169.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2678-90 [10541554.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2104-10 [10706881.001]
  • [Cites] Immunity. 2001 Jan;14(1):45-55 [11163229.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):235-41 [11224523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3788-93 [11891328.001]
  • [Cites] Nat Immunol. 2002 May;3(5):483-8 [11927911.001]
  • [Cites] Nature. 1985 May 16-22;315(6016):232-3 [3873615.001]
  • [Cites] Cell. 1991 Aug 9;66(3):533-40 [1868548.001]
  • [Cites] Nature. 1995 Jun 29;375(6534):795-8 [7596413.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1930-44 [8756350.001]
  • [Cites] Annu Rev Immunol. 1997;15:433-52 [9143695.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4782-91 [9234734.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Curr Opin Hematol. 2004 Nov;11(6):426-33 [15548998.001]
  • [Cites] Nat Rev Immunol. 2005 Jun;5(6):497-508 [15928681.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):881-8 [16056227.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1329-42 [16682500.001]
  • [Cites] Blood. 2006 Jul 1;108(1):305-10 [16507772.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Cell. 2002 Jun 28;109(7):811-21 [12110179.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11322-7 [12172006.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2797-803 [12517816.001]
  • [Cites] EMBO J. 2003 Nov 3;22(21):5780-92 [14592976.001]
  • [Cites] EMBO Rep. 2003 Nov;4(11):1067-72 [14566327.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):451-61 [14706337.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1696-702 [15187027.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • (PMID = 18981238.001).
  • [ISSN] 1540-9538
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE12948
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI045846; United States / NCI NIH HHS / CA / P01 CA109901; United States / NCI NIH HHS / CA / T32 CA070083; United States / NCI NIH HHS / CA / T32-CA70083; United States / NIAID NIH HHS / AI / R01 AI45846; United States / NCI NIH HHS / CA / CA109901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Notch1 protein, mouse; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2585834
  •  go-up   go-down


88. Wündisch T, Mösch C, Neubauer A, Stolte M: Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma: Results of a 196-patient series. Leuk Lymphoma; 2006 Oct;47(10):2110-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma: Results of a 196-patient series.
  • Prospective studies have reported ongoing remissions in most patients with localized Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma after curing the infection.
  • Only a minority had a complete staging, and it may be expected that there is a significant group of patients with an unrecognized higher stage in this cohort.
  • [MeSH-major] Anti-Infective Agents / pharmacology. Gastric Mucosa / microbiology. Helicobacter Infections / therapy. Helicobacter pylori / metabolism. Lymphoma, B-Cell, Marginal Zone / microbiology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Remission Induction. Stomach / microbiology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Oct;47(10):2013-4 [17071470.001]
  • (PMID = 17071484.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents
  •  go-up   go-down


89. Bergeron J, Clappier E, Radford I, Buzyn A, Millien C, Soler G, Ballerini P, Thomas X, Soulier J, Dombret H, Macintyre EA, Asnafi V: Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. Blood; 2007 Oct 1;110(7):2324-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TLX1 is a homeodomain transcription factor generally associated with a favorable outcome in T-cell acute lymphoblastic leukemia (T-ALL).
  • We have studied 264 unselected T-ALLs (171 adults and 93 children) and show that T-ALLs expressing high levels of TLX1 (n = 35, 13%), defined as a real-time quantitative polymerase chain reaction (RQ-PCR) level of TLX1 greater than 1.00 ABL, form a homogeneous oncogenic group, based on their uniform stage of maturation arrest and oncogenetic and transcriptional profiles.
  • Prognostic analysis within the adult LALA94 and GRAALL03 prospective protocols demonstrate a better event-free survival (P = .035) and a marked trend for longer overall survival (P = .059) for TLX1-high T-ALLs, while the expression of lower levels of TLX1 does not impact on prognosis.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Alleles. Antineoplastic Combined Chemotherapy Protocols. Chromosomes, Human, Pair 10 / genetics. Female. Genotype. Humans. Immunogenetics. Karyotyping. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. Survival Rate. Transcription, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609427.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 143275-75-6 / TLX1 protein, human
  •  go-up   go-down


90. Owens BM, Hawley TS, Spain LM, Kerkel KA, Hawley RG: TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br J Haematol; 2006 Jan;132(2):216-29
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage.
  • The TLX1/HOX11 homeobox gene is frequently activated in T-cell acute lymphoblastic leukaemia (T-ALL) by the t(10;14)(q24;q11) and t(7;10)(q35;q24) chromosomal translocations or by as yet unknown transcriptional mechanisms in the absence of 10q24 cytogenetic abnormalities.
  • Interestingly, enforced expression of TLX1 disrupted the differentiation of murine fetal liver precursors and human cord blood CD34(+) stem/progenitor cells prior to the DP thymocyte stage.
  • Although differentiation arrest was associated with an increased percentage of apoptotic thymocytes, it could only be partially bypassed by coexpression of transgenic BCL2.
  • Mutation of the invariant asparagine residue at position 51 of the homeodomain - which is required for efficient DNA binding - released the block, consistent with the notion that TLX1 inhibits thymocyte differentiation and promotes T-cell oncogenesis by functioning as a transcription factor.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1995 Oct 5;11(7):1333-8 [7478554.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1875-7 [7569929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10302-6 [7479772.001]
  • [Cites] Gene Ther. 1994 Mar;1(2):136-8 [7584069.001]
  • [Cites] Biochemistry. 1995 Nov 7;34(44):14601-8 [7578067.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2180-6 [8630377.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10297-302 [8816794.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):337-45 [9000579.001]
  • [Cites] Nature. 1997 Jan 30;385(6615):454-8 [9009195.001]
  • [Cites] Immunity. 1997 Mar;6(3):265-72 [9075927.001]
  • [Cites] Cell. 1997 Jun 27;89(7):1011-9 [9215624.001]
  • [Cites] Cell. 1997 Jun 27;89(7):1033-41 [9215626.001]
  • [Cites] Gene Ther. 1997 Oct;4(10):1013-22 [9415306.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):5735-41 [9637482.001]
  • [Cites] Blood. 1998 Aug 1;92(3):877-87 [9680355.001]
  • [Cites] Immunity. 1999 May;10(5):537-46 [10367899.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1334-41 [10415032.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4173-80 [15054041.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4849-52 [15713800.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1705-8 [15990867.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5561-75 [15897879.001]
  • [Cites] Mol Ther. 2000 Nov;2(5):458-69 [11082319.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2209-17 [11160274.001]
  • [Cites] Stem Cells. 2001;19(2):118-24 [11239166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):609-14 [11149941.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:724-31 [11268400.001]
  • [Cites] Leuk Lymphoma. 2000 Oct;39(3-4):241-56 [11342305.001]
  • [Cites] J Exp Med. 2001 Jun 18;193(12):1431-7 [11413198.001]
  • [Cites] J Exp Med. 2001 Jul 2;194(1):99-106 [11435476.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):86-91 [11544531.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2325-31 [11859122.001]
  • [Cites] Curr Opin Immunol. 2002 Apr;14(2):200-6 [11869893.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3475-95 [12032783.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):3021-9 [12218117.001]
  • [Cites] Stem Cells. 2002;20(5):364-79 [12351808.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3828-31 [12393673.001]
  • [Cites] Nat Rev Immunol. 2002 Nov;2(11):888-97 [12415312.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46289-97 [12228235.001]
  • [Cites] Trends Immunol. 2003 Apr;24(4):197-206 [12697452.001]
  • [Cites] Leukemia. 2003 May;17(5):887-93 [12750702.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4966-74 [12586625.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1851-7 [12970786.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):311-9 [14585358.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5230-9 [15100261.001]
  • [Cites] J Exp Med. 2004 Sep 6;200(5):659-69 [15353558.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Methods Mol Med. 2005;105:311-22 [15492404.001]
  • [Cites] Science. 1991 Jul 5;253(5015):79-82 [1676542.001]
  • [Cites] Semin Immunol. 1990 Jan;2(1):51-8 [2129901.001]
  • [Cites] EMBO J. 1991 Oct;10(10):2905-10 [1717256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8900-4 [1681546.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2996-3003 [1683261.001]
  • [Cites] Cell. 1991 Nov 29;67(5):889-99 [1959134.001]
  • [Cites] J Immunol. 1993 May 15;150(10):4244-52 [8387091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4431-5 [8099440.001]
  • [Cites] J Immunol. 1993 Jul 1;151(1):83-91 [8326141.001]
  • [Cites] J Immunol. 1993 Sep 1;151(5):2546-54 [8360476.001]
  • [Cites] Oncogene. 1994 Jan;9(1):1-12 [7905617.001]
  • [Cites] Immunology. 1994 Jan;81(1):115-9 [8132207.001]
  • [Cites] J Immunol Methods. 1994 Apr 15;170(2):145-57 [8157993.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1587-93 [7520780.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1955-60 [7964471.001]
  • [Cites] Nature. 1995 Mar 2;374(6517):70-4 [7870176.001]
  • [Cites] Immunity. 1994 Jul;1(4):261-7 [7889413.001]
  • (PMID = 16398656.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01HL65519; United States / NHLBI NIH HHS / HL / R01 HL066305-05; United States / NCRR NIH HHS / RR / R24RR16209; United States / NHLBI NIH HHS / HL / R01 HL065519; United States / NHLBI NIH HHS / HL / R01 HL066305; United States / NCRR NIH HHS / RR / R24 RR016209; United States / NHLBI NIH HHS / HL / HL066305-05; United States / NHLBI NIH HHS / HL / R01HL66305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins; 143275-75-6 / TLX1 protein, human
  • [Other-IDs] NLM/ NIHMS51706; NLM/ PMC2431114
  •  go-up   go-down


91. Gualco G, Queiroga EM, Weiss LM, Klumb CE, Harrington WJ Jr, Bacchi CE: Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma. Hum Pathol; 2009 Apr;40(4):565-71
Genetic Alliance. consumer health - Multiple myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.
  • Burkitt lymphoma is a highly aggressive non-Hodgkin lymphoma with endemic, sporadic, and immunodeficiency-associated clinical variants composed of monomorphic medium-sized B cells with a high proliferation rate and a translocation involving the C-MYC locus.
  • Classically, the immunophenotype of Burkitt lymphoma has been considered to be the germinal center type.
  • In most reports, all cases of Burkitt lymphoma are reported to be multiple myeloma 1-negative. multiple myeloma 1 expression is seen in plasma cells and in a small fraction of B cells located in the light zone of germinal centers corresponding to the final step of intra-germinal center B-cell differentiation, and in activated T cells.
  • Therefore, multiple myeloma 1 expression may denote the final step of intra-germinal center B-cell differentiation at the centrocyte stage, as well as the subsequent steps of B-cell maturation toward plasma cells.
  • Twenty-five Burkitt lymphoma cases, including 19 associated with HIV, were reported in one of the few studies in the literature; 2 of these cases showed occasional multiple myeloma 1-positive cells, less than the 20% cutoff for positivity.
  • We studied 222 cases of well-characterized Burkitt lymphoma with the classic phenotype and C-MYC translocation and found 90 cases (40.5%) with multiple myeloma 1 nuclear expression, suggesting a late germinal center stage of differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Am J Clin Pathol. 2008 Dec;130(6):946-56 [19019773.001]
  • [Cites] Leukemia. 2000 Apr;14(4):563-6 [10764139.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):247-57 [11091208.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):686-94 [11455001.001]
  • [Cites] Blood. 2002 Jan 15;99(2):409-26 [11781220.001]
  • [Cites] Br J Haematol. 2002 May;117(2):366-72 [11972519.001]
  • [Cites] Med Sci Monit. 2003 Jan;9(1):HY1-9 [12552250.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):384-92 [15023043.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Science. 1997 Jan 24;275(5299):540-3 [8999800.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] Cytokine Growth Factor Rev. 1997 Dec;8(4):293-312 [9620643.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):790-8 [16203284.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Oncologist. 2006 Apr;11(4):375-83 [16614233.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2495-8 [16760450.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):315-9 [16896892.001]
  • [Cites] Adv Anat Pathol. 2007 Jan;14(1):25-35 [17198308.001]
  • [Cites] Haematologica. 2007 Feb;92(2):267-8 [17296585.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):558-64 [17875505.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1343-50 [17768115.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • [Cites] Leukemia. 2000 Mar;14(3):449-56 [10720141.001]
  • (PMID = 19144381.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / 5U01CA121947; United States / NCI NIH HHS / CA / CA121947-03; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / U01 CA121947-03; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / 5R01CA121935
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Syndecan-1; 0 / interferon regulatory factor-4
  • [Other-IDs] NLM/ NIHMS125062; NLM/ PMC2741026
  •  go-up   go-down


92. Milosevic R, Todorovic M, Balint B, Jevtic M, Krstic M, Ristanovic E, Antonijevic N, Pavlovic M, Perunicic M, Petrovic M, Mihaljevic B: Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma. World J Gastroenterol; 2009 Aug 28;15(32):4009-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma.
  • AIM: To evaluate the clinical characteristics of splenic marginal-zone lymphoma (SMZL) following antigen expression and the influence of therapeutic approaches on clinical outcome and overall survival (OS).
  • The analysis of factors interfering with survival (by the Kaplan-Meier method) revealed that gender, general symptoms, clinical stage, and spleen infiltration type (nodular vs diffuse) had no significant (P > 0.05) effects on the OS.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / surgery. Splenectomy / methods. Splenic Neoplasms / drug therapy. Splenic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / biosynthesis. Antineoplastic Agents / therapeutic use. Disease Progression. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Prognosis. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Ann Hematol. 2009 Apr;88(4):379-81 [18709501.001]
  • [Cites] Arch Surg. 2002 Jan;137(1):64-8 [11772218.001]
  • [Cites] Histopathology. 2002 Feb;40(2):117-26 [11952855.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1648-54 [12176884.001]
  • [Cites] Haematologica. 2003 Jan;88(1):80-93 [12551831.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):95-103 [12573351.001]
  • [Cites] Br J Haematol. 2003 Mar;120(5):759-64 [12614206.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2464-72 [12446449.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2050-7 [15389479.001]
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):211-23 [8554111.001]
  • [Cites] Clin Radiol. 1998 Feb;53(2):137-42 [9502091.001]
  • [Cites] Blood Rev. 2005 Jan;19(1):39-51 [15572216.001]
  • [Cites] Clin Lab Haematol. 2004 Dec;26(6):397-401 [15595997.001]
  • [Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):11-26 [15694182.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1831-8 [15914563.001]
  • [Cites] Hematol Oncol. 2005 Sep-Dec;23(3-4):108-18 [16307458.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4643-9 [16493005.001]
  • [Cites] Pathol Res Pract. 2008;204(1):23-6 [17913385.001]
  • [Cites] Pathologe. 2008 Mar;29(2):136-42 [18214484.001]
  • [Cites] Pathologe. 2008 Mar;29(2):143-7 [18214486.001]
  • [Cites] Am J Clin Pathol. 2008 May;129(5):714-22 [18426730.001]
  • [Cites] J Exp Med. 2008 Jun 9;205(6):1317-29 [18490492.001]
  • [Cites] Cytometry B Clin Cytom. 2008 Sep;74(5):282-6 [18500740.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1621-4 [18305562.001]
  • [Cites] Br J Haematol. 2008 Oct;143(1):71-4 [18671706.001]
  • [Cites] Leuk Lymphoma. 2008;49 Suppl 1:35-42 [18821431.001]
  • [Cites] Hematology. 2008 Oct;13(5):276-81 [18854089.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):883-901, viii [18954742.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:359-64 [19074110.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):129-36 [18718888.001]
  • [Cites] Mod Pathol. 2009 Feb;22(2):206-15 [18820675.001]
  • [Cites] Leuk Lymphoma. 2001 May;41(5-6):593-605 [11378577.001]
  • (PMID = 19705496.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2731951
  •  go-up   go-down


93. Hayat A, O'Brien D, O'Rourke P, McGuckin S, Fitzgerald T, Conneally E, Browne PV, McCann SR, Lawler MP, Vandenberghe E: CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leuk Lymphoma; 2006 Nov;47(11):2371-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia.
  • Chronic lymphocytic leukemia (CLL) follows a variable clinical course which is difficult to predict at diagnosis.
  • We assessed somatic mutation (SHM) status, CD38 and ZAP-70 expression in 87 patients (49 male, 38 female) with stage A CLL and known cytogenetic profile to compare their role in predicting disease progression, which was assessed by the treatment free interval (TFI) from diagnosis.
  • [MeSH-major] Antigens, CD38 / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoglobulin Heavy Chains / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation / genetics. Survival Rate. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Nov;47(11):2261-2 [17107890.001]
  • (PMID = 17107912.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


94. Chen Z, Yoshihara E, Son A, Matsuo Y, Masutani H, Sugie K, Maeda M, Yodoi J: Differential roles of Annexin A1 (ANXA1/lipocortin-1/lipomodulin) and thioredoxin binding protein-2 (TBP-2/VDUP1/TXNIP) in glucocorticoid signaling of HTLV-I-transformed T cells. Immunol Lett; 2010 Jun 15;131(1):11-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential roles of Annexin A1 (ANXA1/lipocortin-1/lipomodulin) and thioredoxin binding protein-2 (TBP-2/VDUP1/TXNIP) in glucocorticoid signaling of HTLV-I-transformed T cells.
  • Thioredoxin binding protein-2 (TBP-2/VDUP1/TXNIP), a regulator of redox reactions, cell growth and lipid metabolism, was also reportedly induced by GC.
  • HTLV-I infected T cells undergo the transition from the IL-2 dependent to IL-2 independent growth during the long-term culture in vitro.
  • We found that these T cells responded to GC with growth arrest and apoptosis in the IL-2 dependent growth stage, whereas they failed to respond to GC after their growth had shifted into the IL-2 independent stage.
  • Here we employed these T cell lines and studied the roles of ANXA1 and TBP-2 in mediating GC-induced apoptosis.
  • In conclusion, these results suggest that TBP-2, but not ANXA1, is directly involved in the switching of GC sensitivity and GC resistance in HTLV-I infected T cell lines, whereas ANXA1 may be a biomarker indicative of the advanced stage of the transformation.
  • [MeSH-major] Annexin A1 / metabolism. Carrier Proteins / metabolism. Cell Transformation, Viral. Glucocorticoids / pharmacology. Human T-lymphotropic virus 1 / physiology. Signal Transduction / drug effects. T-Lymphocytes / virology
  • [MeSH-minor] Apoptosis. Cell Line, Transformed. Cell Proliferation. Gene Expression Regulation. Humans. Interleukin-2 / metabolism. Leukemia-Lymphoma, Adult T-Cell. Lymphocyte Activation

  • MedlinePlus Health Information. consumer health - Steroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20398702.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Carrier Proteins; 0 / Glucocorticoids; 0 / Interleukin-2; 0 / TXNIP protein, human
  •  go-up   go-down


95. Babusíková O, Zelezníková T, Mlcáková A, Kusenda J, Stevulová L: The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia. Neoplasma; 2005;52(6):502-9
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia.
  • Bone marrow hematogones were separately assessed as hematogones 1 population of early stage and hematogones 2 of mid-stage precursor B-cells, respectively.
  • This small B-cell subpopulation was defined by CD10-positivity, coexpressing more mature markers CD19,CD20,CD22 and CD45bright.
  • Increased information on benign B-lymphocyte precursors, especially that of existence of the 3rd type hematogones could provide a basis for better discrimination of B-leukemia cells even in a very small amounts.
  • [MeSH-major] Antigens, CD / analysis. B-Lymphocytes / immunology. Bone Marrow / immunology. Bone Marrow Cells / cytology. Burkitt Lymphoma / diagnosis. Immunophenotyping
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Male. Middle Aged. Prognosis. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284697.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


96. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJ, van Noesel MM, Pieters R: Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia; 2008 Jan;22(1):124-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is characterized by chromosomal rearrangements possibly enforcing arrest at specific development stages.
  • We studied the relationship between molecular-cytogenetic abnormalities and T-cell development stage to investigate whether arrest at specific stages can explain the prognostic significance of specific abnormalities.
  • HOX11 cases were CD1 positive consistent with a cortical stage, but as 4/5 cases lacked cytoplasmatic-beta expression, developmental arrest may precede beta-selection.
  • NOTCH1 mutations were present in all molecular-cytogenetic subgroups without restriction to a specific developmental stage.
  • CALM-AF10 was associated with early relapse.
  • TAL1 or HOX11L2 rearrangements were associated with trends to good and poor outcomes, respectively.
  • Classification into T-cell developmental subgroups was not predictive for outcome.
  • [MeSH-major] Gene Rearrangement / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Neoplasm Recurrence, Local / genetics. Receptor, Notch1 / genetics
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors / genetics. Cell Lineage. Child. Female. Homeodomain Proteins / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Mutation / genetics. Oncogene Proteins, Fusion / genetics. Prognosis. Proto-Oncogene Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928886.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AF10-CALM fusion protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / TLX3 protein, human; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


97. Alvaro-Naranjo T, Lejeune M, Salvadó-Usach MT, Bosch-Príncep R, Reverter-Branchat G, Jaén-Martínez J, Pons-Ferré LE: Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma; 2005 Nov;46(11):1581-91
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients.
  • The present study aimed to describe the general tissular composition of the immune infiltrate observed in Hodgkin's lymphoma (HL) and its possible relationship with clinical and survival prognostic factors.
  • Patients with low numbers of infiltrating CD8, CD 56, CD 57+cells and high numbers of Granzyme B and TIA-1+cells presented a significantly unfavourable clinical course (presence of leukocytosis, B symptoms, advanced clinical stage (III/IV), non-responding patients).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Count. Child. Dendritic Cells / pathology. Female. Granzymes. Humans. Immunohistochemistry. Killer Cells, Natural / pathology. Male. Middle Aged. Poly(A)-Binding Proteins. Prognosis. RNA-Binding Proteins / analysis. Retrospective Studies. Serine Endopeptidases / analysis. Survival Analysis. T-Lymphocytes / pathology. T-Lymphocytes, Cytotoxic / pathology. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236613.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Poly(A)-Binding Proteins; 0 / RNA-Binding Proteins; 0 / TIA1 protein, human; EC 3.4.21.- / GZMB protein, human; EC 3.4.21.- / Granzymes; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


98. Ozçelik T, Ozkalemkaş F, Kocaeli H, Altundal Y, Ener B, Ali R, Ozkocaman V, Hakyemez B, Tunali A: [Successful treatment of neuroaspergillosis in a patient with acute lymphoblastic leukemia: role of surgery, systemic antifungal therapy and intracavitary therapy]. Mikrobiyol Bul; 2009 Jul;43(3):499-506
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of neuroaspergillosis in a patient with acute lymphoblastic leukemia: role of surgery, systemic antifungal therapy and intracavitary therapy].
  • We report here a case of cerebral aspergillosis in a 34-years-old man with acute lymphoblastic leukaemia who was successfully treated with a combination of aggressive neurosurgery, intracavitary instillation of amphotericin B and voriconazole.
  • However, leukemia relapsed.
  • It is stated that in patients with neuroaspergillosis radical neurosurgery leads to better outcomes if performed at an earlier stage.
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillus flavus / isolation & purification. Neuroaspergillosis / drug therapy. Neuroaspergillosis / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Amphotericin B / administration & dosage. Amphotericin B / therapeutic use. Chemotherapy, Adjuvant. Drug Therapy, Combination. Echinocandins / administration & dosage. Echinocandins / therapeutic use. Fatal Outcome. Humans. Injections, Intraventricular. Male. Pyrimidines / administration & dosage. Pyrimidines / therapeutic use. Triazoles / administration & dosage. Triazoles / therapeutic use. Voriconazole

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795628.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  •  go-up   go-down


99. Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, Leeping M, Prevalsek D, Jaeger G, Ledderose G, Mautner J, Hammerschmidt W, Schendel DJ, Kolb HJ: Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood; 2010 Apr 8;115(14):2960-70
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Posttransplantation lymphoproliferative disease (PTLD) associated with Epstein-Barr virus (EBV) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation.
  • No response was seen in 3 patients who had late-stage disease with multiorgan dysfunction at the time of T-cell transfer.
  • In 3 patients who received T cells at an earlier stage of disease, we observed complete and stable remission of PTLD.
  • Two patients have remained free from EBV-associated disease for more than 2 years.
  • CD8(+) T cells specific for EBV early antigens rapidly expanded after T-cell transfer, temporarily constituted greater than 20% of all peripheral blood lymphocytes, and were maintained throughout the observation period.
  • Thus, a rapid and sustained reconstitution of a protective EBV-specific T-cell memory occurred after the infusion of small numbers of directly isolated EBV-specific T cells.
  • [MeSH-minor] Adult. Anemia, Aplastic / immunology. Anemia, Aplastic / therapy. Anemia, Aplastic / virology. Female. Humans. Immunologic Memory. Interferon-gamma. Leukapheresis / methods. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / therapy. Leukemia, Myeloid, Acute / virology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Lymphoma, T-Cell / virology. Male. Middle Aged. Remission Induction. Stem Cell Transplantation. Transplantation, Homologous

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20103780.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Peptides; 0 / Viral Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


100. Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF, Kay NE, Shanafelt TD: Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol; 2008 May;141(5):607-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia.
  • Patients with chronic lymphocytic leukaemia (CLL) have a variable clinical course.
  • The absolute number of T-cell and natural killer (NK)-cells was calculated for 166 consecutive patients with CLL evaluated by flow cytometry at Mayo Clinic < or = 2 months of diagnosis.
  • The size of the T-cell/NK-cell compartment relative to the size of the malignant monoclonal B-cell (MBC) compartment was evaluated by calculating NK:MBC and T:MBC ratios.
  • Higher T:MBC and NK:MBC ratios were observed among patients with early stage and mutated IGHV genes (all P < or = 0.0003).
  • As continuous variables, both T:MBC ratio (P-value = 0.03) and NK:MBC ratio (P-value = 0.02) were associated with time to treatment (TTT).
  • On multivariate Cox modelling including stage, CD38, absolute MBC count, NK:MBC ratio and T:MBC ratio, the independent predictors of TTT were stage, T:MBC ratio and NK:MBC ratio.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Dec 1;94(11):3889-96 [10572105.001]
  • [Cites] Leukemia. 1997 Jun;11(6):775-8 [9177426.001]
  • [Cites] Haematologica. 2001 Jan;86(1):8-12 [11146563.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):854-61 [11843819.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1057-63 [12689926.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1202-10 [14576043.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Mayo Clin Proc. 1994 Apr;69(4):323-8 [8170175.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2506-12 [15972449.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Mar;6(5):393-8 [16640816.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3218-9; author reply 3219-20 [16809747.001]
  • [Cites] Br J Haematol. 2006 Sep;134(6):596-601 [16889618.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4634-41 [17008705.001]
  • [Cites] Br J Haematol. 2007 Jun;137(5):409-15 [17433025.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1885-91 [17568813.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2554-6 [17581607.001]
  • [Cites] Haematologica. 1999 Dec;84(12):1094-9 [10586211.001]
  • (PMID = 18384436.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / CA113408; United States / NCI NIH HHS / CA / K07 CA094919; United States / NCI NIH HHS / CA / CA94919; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / K23 CA113408
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  • [Other-IDs] NLM/ NIHMS458045; NLM/ PMC3840945
  •  go-up   go-down






Advertisement